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Glossary 
Antenatal Before birth; during or relating to pregnancy. 
Antenatal screening Testing of pregnant woman to detect conditions in the woman that may 
threaten the health of the foetus or child.  
Antenatal screening coverage  Proportion of pregnant women screened of the total eligible. 
Infant A child of less than 12 months of age. 
Mother-to-child transmission Transmission of an infectious agent from mother to child before birth, during 
labour and delivery, or during infancy (the first year of life). Also referred to as 
vertical transmission. 
Newborn A child of less than 1 month of age. 
Neonatal Of, relating to, or affecting the newborn during the first month after birth. 
Notifiable infection An infection that must be reported to health authorities. 
Diagnostic testing Applying a test for the purpose of identifying a health condition or disease. 
Opt-in testing Individuals seeking care are informed that testing is recommended. The 
individual is required to give explicit consent before the test is performed. 
Opt-out testing Testing is performed as part of routine care. Pre-test information is made 
available and consent is assumed unless the individual explicitly declines 
testing.  
Prenatal Before birth; during or relating to pregnancy (synonym for antenatal). 
Screening The systematic application of tests, examinations, or other procedures with the 
intention of identifying previously unrecognised health conditions. The relevant 
population is dependent on the condition to be identified. 
Selective screening Testing targeting subsets of the population, usually groups considered to be 
disproportionately affected or at increased risk. 
Universal screening Systematic testing applied to the entire relevant population, which can be 
either mandatory or voluntary. 
Vertical transmission See mother-to-child-transmission. 
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Key findings 
These findings are based on the analysis of an online survey taken in June and July 2013. The survey was filled in 
by national experts appointed by the Member State based on their expertise in antenatal screening programmes. 
A total of 26 EU/EEA countries participated in the survey. 
Antenatal strategies and practices 
National guidance, recommendations or strategy for antenatal care: The majority (25/26) of EU/EEA 
countries that responded to the survey, provide antenatal care services based on national guidance, 
recommendations or strategy, however compliance with such guidelines is suboptimal in some countries. 
Implementation of antenatal screening for infections: A high proportion of EU/EEA countries implement 
antenatal screening for HIV (24/26), HBV (23/26) and syphilis (26/26). Fewer countries have implemented rubella 
susceptibility screening programmes (14/26).  
Strategies for antenatal screening: Opt-out screening is the most common strategy for antenatal screening for 
HIV (15/23), HBV (14/23), syphilis (16/26) and rubella susceptibility (9/14) in EU/EEA countries.  
Financing of antenatal screening: Antenatal screening programmes for infections are for the most part publicly 
funded and provided through national health services in the EU/EEA; in several countries, however, screening is 
only covered through a pre-existing health insurance policy.  
Timing of screening and coverage: Countries that have antenatal screening policies for infections and rubella 
susceptibility most often recommend that this screening is undertaken in the first trimester of pregnancy for HIV 
(21/23), HBV (14/20), syphilis (22/24) and rubella susceptibility (10/11). Coverage of screening was estimated to 
be ≥95% for HIV, HBV and syphilis in the majority of responding countries.  
Laboratory methods for antenatal screening: HIV antibody/antigen (Ab/Ag) combination tests are used in 
18/23 countries. HBsAg testing is used in the 20 countries that provided information on HBV antenatal screening. 
Both treponemal and non-treponemal tests are in use for antenatal screening for syphilis in 14/24 EU/EEA 
countries. 
Diagnosis during pregnancy: 15/21 EU/EEA countries reported capacity to distinguish between HIV infections 
that were known before pregnancy and HIV infections newly diagnosed during the current pregnancy through 
screening. Eight of 13 countries reported that more than 30% of HIV-positive pregnant women were newly 
diagnosed through antenatal screening. Nine of 22 countries can identify whether HBV infection is newly diagnosed 
during the current pregnancy; the percentage ranged from 0.5 to 100 in six reporting countries.  
Testing of children born to positive mothers: In all responding countries, children born to HIV-, HBV-, and 
syphilis-positive mothers, or mothers confirmed with rubella infection during pregnancy, are tested. Exceptions are 
Finland, where syphilis testing is not done if the mother has been treated during pregnancy, and Italy and Poland, 
who do not test children born to HBV-positive mothers.  
Referral to healthcare: Antenatal screening in the EU/EEA is most often performed in specialist healthcare 
services (obstetricians and gynaecologists), with midwives and general practitioners also involved in screening in 
some countries.  
Treatment/prophylaxis of the mother and the child: All responding EU/EEA countries recommend 
antiretroviral therapy for HIV-positive pregnant woman and antiretroviral prophylaxis for the newborn. Penicillin is 
the recommended treatment for both syphilis and congenital syphilis. Prevention of mother-to-child transmission of 
HBV is based on a combination of vaccination (first dose at birth) and administration of HBV immunoglobulin to the 
child in 18/21 responding countries. 
Populations at risk of mother-to-child transmission: Ethnic minority pregnant women and migrants from 
high-prevalence areas outside the EU were identified by country responders as the population at highest risk of 
mother-to-child transmission of HIV, HBV, syphilis and rubella, followed by women presenting or being reached late 
for antenatal care. People who inject drugs and mobile populations like intra-EU-migrants were also identified as 
high-risk populations. 
Challenges for effective antenatal screening: Common challenges for effective antenatal screening reported 
by EU/EEA countries were the deficiencies in data reporting and collection at the national level, insufficient capacity 
to reach groups at risk, and a general lack of resources for these activities. 
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Antenatal screening for infections in the EU/EEA 
HIV: All surveyed countries with the exception of Hungary and Slovenia (24/26) implement antenatal HIV 
screening, with opt-out screening being the most common (15/24) strategy. Testing coverage is over 95% in the 
first trimester in 8/15 countries and over 95% for testing at any time during pregnancy in 12/18 countries. Ten 
countries reported repeat testing later in pregnancy, either as a general recommendation (Estonia, Lithuania, 
Romania, Slovakia and Spain) or among high-risk groups (France, Greece, Ireland, Italy and Norway).  
In 2013, 19 countries reported a total of 91 HIV MTCT (mother-to-child transmission) cases in persons born in the 
reporting country, with MTCT rates per 100 000 births between 0.7 (Germany) and 43.7 (Latvia); ten countries had 
no MTCT reports in people born in the reporting country (Annex 2). 
Hepatitis B: Antenatal screening for hepatitis B (HBV) is implemented in 23/26 countries (not in Lithuania, 
Norway and Romania); in the majority of countries that reported data (8/13), screening coverage was ≥95%. 
However, data from many countries were not collected at the national level, making it difficult to evaluate the 
screening situation. Identification of MTCT cases in EU/EEA residents was also difficult because datasets submitted 
to TESSy showed a low level of completeness. 
Except for Denmark, Finland, Iceland, Norway, Sweden and the UK, where vaccination is targeted only at people at 
risk, all countries run universal childhood HBV vaccination programmes; coverage is between 74% and 99%. In 
countries where the first dose of vaccine is not routinely offered at birth, newborns of mothers from risk groups are 
targeted for vaccination.  
Syphilis: All participating EU/EEA countries (26/26) implement antenatal screening. Most (22/24) countries test 
pregnant women for syphilis during the first trimester of pregnancy. Seven countries reported repeat testing during 
the third trimester of pregnancy as a general recommendation and another three countries offer repeat testing for 
women in risk groups. The reported coverage of antenatal screening of syphilis was high: 14/18 countries reported 
a coverage of ≥95%, while three reported a coverage of ≥90%.  
In 2013, 64 cases of congenital syphilis were reported from nine countries, with rates per 100 000 live births 
between 0.3 (Germany) and 40.6 (Bulgaria); twelve countries reported zero cases of congenital syphilis (Annex 2).  
Rubella: 14/26 countries implement national rubella susceptibility screening. In ten countries, screening was 
discontinued due to low incidence of rubella and high vaccination coverage. The countries that still screen for 
rubella susceptibility rarely keep a national database. Testing coverage was ≥95% in 4/5 countries that reported 
data. A lack of available data describing MTCT of rubella and levels of population susceptibility was identified as the 
biggest challenge for the implementation of effective antenatal screening policies for rubella.  
In 10/11 countries, antenatal screening for rubella susceptibility is recommended during the first trimester of 
pregnancy, but it can also be offered as preconception care. In 2013, 45 of the 49 cases of congenital rubella 
reported in the EU/EEA occurred in Romania, a country where antenatal screening is not implemented.  
Conclusions 
The results of this survey and the available surveillance data indicate that there is ongoing mother-to-child 
transmission of HIV, hepatitis B, syphilis and rubella, especially among certain high-risk populations. This suggests 
that the effectiveness of the antenatal screening practice – despite of considerable breaths – can be optimised. 
Factors that compromise effectiveness include low screening coverage, limited access to antenatal care services, 
and limited access to testing for several subpopulations. 
While the case rates of MTCT of HIV and congenital syphilis are below the WHO global targets for the elimination 
in the EU/EEA (<50 cases per 100 000 live births), antenatal care coverage and testing still needs to be scaled up 
in several countries, with increased attention to be given to improving access to antenatal screening for vulnerable 
groups.  
Few countries collect data robust enough for a comprehensive evaluation of antenatal screening programme 
effectiveness, and even fewer countries make the results of such evaluations publically available. It would therefore 
be helpful to develop a set of process and outcome indicators to guide countries in the monitoring and evaluation 
of antenatal screening programme effectiveness. 
Several national surveillance systems in EU/EEA countries do not currently identify and record all MTCT cases in 
people born in the reporting country. Recording these cases is essential for the informative value of national 
screening programmes. In addition, the notification of congenital syphilis cases is not mandatory in some 
countries. Enhanced surveillance of MTCT cases with comprehensive collection of information about the mother 
and the child would improve the assessment of the incidence of MTCT and would provide valuable information on 
risk factors. This information could then be used to inform national policies and would probably lead to scaled-up 
antenatal screening for the most-at-risk subpopulations.  
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Ongoing mother-to-child transmission particularly affects certain vulnerable groups that are not adequately reached 
by, or do not have access to, testing services and prevention interventions that are available to the majority of the 
population. Member States should consider targeted interventions for such populations at risk, based on an 
assessment of disease epidemiology and risk profile.  
ECDC is currently developing an evidence-based guidance to strengthen antenatal screening among vulnerable 
groups. The guidance will answer two central questions: a) What are the decisive elements of national 
programmes for antenatal infection screening with regard to their effectiveness and b) how can vulnerable groups 
be reached to increase the uptake of prenatal care in order to prevent or reduce mother-to-child transmission of 
infectious diseases.  
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1 Background 
1.1 Demographics  
In 2013, 5.1 million children were born in EU countries, a crude birth rate of 10.0 live births per 1 000 inhabitants 
(Eurostat). The number of live births was highest in France (820 830) and the lowest in Malta (4 032) (Figure 1). 
Ireland had the highest birth rate (15.0) and Portugal the lowest (7.9) (Figure 2) [1]. Among the European 
Economic Area (EEA) countries, Iceland and Norway had birth rates above the EU rate (10.0), 13.4 and 11.6, 
respectively.  
Figure 1. Number of live births in EU/EEA countries, 2013  
 
Source: Eurostat [1] 
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Figure 2. Crude birth rate per 1 000 inhabitants, EU/EEA, 2013  
 
Note: The crude birth rate relates the number of births during the year to the average population in that year. 
Source: Eurostat  [1]  
Despite the existence of effective preventive interventions, the transmission of infections from mother to child 
before birth, during the birthing process and in infancy still occurs in several European countries [2,3].  
1.2 Epidemiological context  
The vertical transmission of HIV, syphilis, HBV and rubella, as shown by surveillance data, is characterised by 
different patterns in the EU/EEA countries. These patterns are a result of the heterogeneity in case reporting, 
differences in antenatal screening policies and practices, prevalence rates of infections in women of reproductive 
age, and vaccination policies. Antenatal screening programmes may also vary across countries and may be affected 
by a number of factors such as programme implementation, access to antenatal care, integration of antenatal 
screening in overall antenatal care, timeliness, frequency of testing, and notification of the results. 
HIV 
Mother-to-child transmission (MTCT) is the most significant mode of HIV infection in children worldwide [4]. 
Without intervention, the risk of HIV transmission from infected mother to child ranges from 15% to 30% during 
pregnancy/delivery to between 10% and 20% during breastfeeding. Risk factors for MTCT are high viral load, low 
CD4 cell count, and advanced clinical stage of the mother. With a combination of appropriate interventions 
including anti-retroviral therapy (ART) for the mother, anti-retroviral prophylaxis for the newborn, and avoidance of 
breastfeeding, the risk of MTCT of HIV can be reduced to 1–2% [5]. 
In 2013, 29 157 new HIV diagnoses were reported in the 30 EU/EEA countries, a rate of 5.7 per 100 000 
population. The overall rate for women was 2.6 per 100 000 population (range: 0.3 in Hungary, 17.8 in Estonia) 
(Figure 3 a). Among pregnant women, HIV prevalence was the highest in Estonia and Ireland (over 0.3%); 
between 0.1% and 0.2% in Latvia, Romania, Spain and the UK; and below 0.1% in 16 European countries 
(numbers are from 2000 to 2004) [6].  
Although policies regarding antenatal HIV screening are implemented in the majority of EU/EEA countries [7], 
MTCT accounted for 0.7% (218 cases) of all new HIV diagnoses [2]. While 25% of the individuals infected through 
MTCT originated from countries with generalised epidemics, 39% (85/218) originated from an EU/EEA reporting 
country. This indicates remaining challenges for the existing antenatal screening programmes [2]. 
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Figure 3. Notification rates of HIV and syphilis per 100 000 women, EU/EEA, 2013 
a) HIV 
 
b) Syphilis  
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HBV 
High maternal viral load is the most important factor in vertical transmission of HBV and is significantly correlated 
with e-antigen (HBeAg) positivity. Without intervention, the risk of transmission from an HBeAg-positive mother is 
between 70% and 90%, and <10% for an HBeAg-negative/HBsAg-positive mother [8]. 
MTCT is preventable in 95% of all cases through the administration of vaccine and immunoglobulin to the baby at 
birth [8]. With no immunoprophylaxis, more than 90% of infants infected by their HBeAg-/HBsAg-positive mothers 
will go on to develop chronic infection. The earlier in life the infection occurs, the higher is the risk for chronicity. 
The chronicity rate after HBV infection decreases to approximately one quarter (23%) in children infected at 
preschool age and to 2.7% in young adults. Approximately 25% of those who become chronically infected during 
childhood will die prematurely from cirrhosis or liver cancer [9]. 
In 2013, 2 896 cases of acute HBV and 13 629 cases of chronic HBV were reported by 28 EU/EEA countries, with 
an overall male-to-female ratio of 1.5:1 [10]. MTCT was the most common route of transmission for chronic HBV 
(43.5%), with a high proportion of these cases being imported. Comparison of rates of HBV in women is difficult 
due to the heterogeneity in the case definitions used by each country. Rate comparisons are further complicated by 
the largely asymptomatic nature of the infection (especially chronic), which means that reported cases are more 
indicative of differences in testing than the underlying epidemiology. Among pregnant women, the reported HBV 
prevalence ranges between 0.14% (Finland) and 1.15% (Greece) [11]. 
Syphilis 
Transmission of syphilis from mother-to-child depends upon the extent of bacteraemia in the pregnant woman, 
which declines gradually during the course of infection. The risk of vertical transmission is 70% for primary and 
secondary syphilis, 40% for early latent and 10% for late latent syphilis [12]. Penicillin is an effective treatment for 
syphilis during pregnancy; infants born to treated mothers have only a 1–2% risk of infection [13]. 
Adverse outcomes of untreated pregnancies include: early foetal loss or stillbirth (21%), neonatal death (9%), 
prematurity or low birth weight (6%), and clinical evidence of syphilis in the newborn (16%) [14]. Globally, MTCT 
of syphilis may contribute to up to one quarter of all stillbirths and 11% of neonatal deaths [15]. 
In 2013, 22 227 syphilis cases were reported in 29 EU/EEA countries, resulting in an overall syphilis rate of 5.5 per 
100 000 population. The rate among women was 1.6 per 100 000, ranging between 0.3 (Croatia, Slovenia) and 7.7 
(Lithuania) (Figure 3 b). In 2013, 64 cases of congenital syphilis were reported from 9 countries; 12 countries 
reported zero cases. The overall rate in the EU/EEA was 2.0 per 100 000 live births. The majority of the cases were 
reported by Bulgaria (27), Poland (19) and Portugal (5) [3]. These numbers appear to be relatively low, but it is 
likely that congenitally transmitted syphilis infections are underreported [16]. 
Rubella 
Rubella virus is spread in airborne droplets and through respiratory secretions. If infected during pregnancy, 
women may transmit the infection to their foetus. Transmission of infection is highest, up to 80%, during the first 
trimester, declining to a minimum of 25% at the end of the second trimester. There is no treatment for rubella but 
MTCT can be prevented by ensuring that all women who plan to get pregnant are immune or have been 
immunised against rubella [17]. 
Infection with rubella has severe adverse outcomes such as miscarriage, stillbirth and a series of birth defects. 
Children with a congenital rubella syndrome can suffer hearing impairments, eye and heart defects and other 
lasting disabilities, including autism, diabetes mellitus and thyroid dysfunction. Rubella is most damaging during the 
first trimester. After the fourth month, infection of the mother with rubella is less likely to harm the foetus [17]. 
In 2013, 38 847 rubella cases were reported from 27 EU/EEA countries, with 12.6% of cases in females. Most 
(99%) cases were associated with the large rubella outbreak in Poland where two cases of congenital rubella were 
reported in 2013 [18]. In Romania, 45 cases of congenital rubella were reported in 2013 after an outbreak in 2011 
and 2012 when 119 rubella cases were reported among pregnant women [19]. 
Vaccination against rubella is part of routine childhood immunisation schedules in Europe. However, year of 
introduction, vaccination strategies, schedules and coverage vary by country, which leaves parts of the population 
susceptible to rubella infection. The increased circulation of rubella among young adults in Europe inevitably 
increases the risk of congenital rubella syndrome [20]. 
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1.3 Antenatal screening for infections  
Screening is defined as the systematic application of tests, examinations, or other procedures with the intention of 
identifying previously unrecognised health conditions [21]. Antenatal screening involves the testing of pregnant 
women for evidence of infection, or in the case of rubella, for lack of protective immunity, in an effort to prevent 
vertical transmission through specific interventions, reducing harm to both mother and child.  
Guidelines, recommendations and regulations that govern the organisation and implementation of antenatal 
screening and intervention services may vary between countries and regions and even between service providers. 
Antenatal screening can be implemented in many ways; it can be targeted (selective) or population-based 
(universal or mass-screening), depending on the structure of maternal and child health services in different 
countries or regions. Testing in pregnancy is rarely mandatory; opt-out and opt-in screening are the most common 
forms of voluntary antenatal screening  [7]. The funding, division of labour between public and private health 
services and cost to the patient may vary widely depending on how healthcare and social welfare services are 
organised. Access to antenatal services may differ by country in accordance to national laws and regulations, as 
well as health insurance coverage. 
1.4 Effectiveness of antenatal screening programmes  
The effectiveness of an antenatal screening programme is measured through monitoring of how well the system 
performs in preventing the MTCT of the infections that the screening and subsequent interventions target. This can 
be done by comparing the predicted/estimated number of infections among newborns that would occur without 
the interventions to those that actually occur. To be able to measure this, reliable estimates of the occurrence of 
disease among pregnant women are needed, as well as equally reliable estimates of the occurrence of disease 
among their offspring. Effectiveness can also be described as a function of the success at the different stages of 
the continuum of antenatal care: how many pregnant women at risk are linked into and retained in care, offered 
antenatal screening, are notified of their test results and subsequently are treated, or, in the case of rubella, 
vaccinated to prevent MTCT in future pregnancies.  
To ensure optimal effectiveness, antenatal preventive interventions should be based on the best scientific evidence 
and cost effectiveness analyses and take into account the local epidemiology of specific infections, priorities in 
public health, and resources. A list of evidence-based effective interventions for the prevention of MTCT was 
published by the World Health Organization in 2005 [22]. Recent reports from Denmark and the Netherlands 
suggest that replacing selective screening programmes based on risk factors with universal screening programmes 
with an opt-out strategy are effective in reducing the transmission rates of HIV, HBV and syphilis [23-25]. 
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2 Survey in the Member States 
2.1 Aims and objectives  
Data needed to evaluate the effectiveness of antenatal screening programmes of HIV, HBV, syphilis and rubella 
susceptibility in the EU/EEA were collected through a Member State survey. The survey had the following 
objectives: 
 Describe current practice and map existing policies for the antenatal screening of infections in EU/EEA 
countries. 
 Define the effectiveness of antenatal screening in terms of proportion of pregnant women screened, 
proportion of follow-up of positive test results, and provision of mother-to-child transmission prevention 
services.  
 Identify subpopulations vulnerable to MTCT of HIV, HBV, syphilis and rubella. 
 Understand the current challenges for antenatal screening in Member States in order to inform the 
development of ECDC guidance for effective antenatal screening.  
2.2 Methods  
Survey roll-out 
An online survey was undertaken in June and July 2013 [26]. To identify survey responders, a letter was sent to 
the ECDC Coordinating Competent Body1 in each Member State, inviting them to nominate national experts who 
could best provide information on national policies and practices. Depending on country arrangements, up to five 
experts were appointed in each country to answer the survey, based on their involvement and expertise in 
antenatal screening programming.  
The survey questionnaire was developed in English and consisted of five sections: one general part (Annex 3) and 
four infection-specific questionnaires (Annexes 4–7). The general questionnaire included questions on antenatal 
care policies, implementation of antenatal screening for HIV, HBV, syphilis and rubella susceptibility and type of 
strategies, as well as on vaccination programmes for HBV. The specific questionnaires covered the following items 
for each infection:  
 Organisation of antenatal screenings, including details on antenatal care providers, testing methods, timing 
of testing, funding 
 Management of infection during pregnancy, type of interventions to prevent mother-to-child transmission 
during antenatal and neonatal period 
 Indicators for antenatal screening effectiveness (i.e. either raw data or country estimates for testing 
coverage, uptake of MTCT interventions) 
 List of populations groups at risk for not being reached by antenatal screening and thus vulnerable to MTCT 
 Country self-assessment of challenges in achieving MTCT elimination. 
Responses were stored on a Webropol platform on a secure space managed by THL Helsinki and transferred to an 
Excel file at the end of the survey.  
The survey was piloted by experts from Denmark, the Netherlands and Northern Ireland (UK) in April 2013. 
Comments and suggestions were incorporated in the revised version of the questionnaires.  
Screening strategies definitions 
The survey responders were invited to select the type of antenatal screening implementation that best described 
their national profile. The following options were available: opt-in screening – ‘pregnant woman is offered testing 
and if she agrees to testing, she must provide explicit consent’, opt-out screening – ‘pregnant woman is informed 
that testing will take place as part of the antenatal care, the test will be performed unless she explicitly declines’ 
and universal screening – ‘testing offered to all, none of the previous strategies apply’. If a country offered 
screening for selective risk groups, responders were asked to specify which groups.  
 
                                                                    
1 http://www.ecdc.europa.eu/en/aboutus/Competent%20bodies/Pages/Competent_bodies.aspx  
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Data on mother-to-child transmission in the reporting country  
HIV and HBV cases attributed to MTCT and congenital syphilis cases were retrieved from The European 
Surveillance System (TESSY) for the reporting year 2013 (Annex 2). Country of birth, country of nationality, region 
of origin, probable country of infection and importation status were used to identify HIV and HBV MTCT cases in 
persons born in the reporting country.  
Indicators of effectiveness  
Testing coverage and coverage of prevention interventions in the mother or in the child were collected as part of 
the assessment of the effectiveness of antenatal screening. The antenatal screening testing coverage, defined as 
the proportion of pregnant women tested, was reported by survey responders based on existing national data; if 
no national data were available, responders estimated the coverage. The same approach was used to determine 
the coverage for interventions.  
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3 Results  
3.1 Member States responses to survey 
Reponses to the general section of the questionnaire on antenatal screening were received from 26/30 countries 
(86.7%). For the infection-specific questionnaires, number were slightly lower: 25 countries (83.3%) filled in 
questionnaires for HIV, 22 countries (73.3%) for HBV, 24 countries (80%) for syphilis, and 22 countries (73.3%) 
for rubella susceptibility (Annex 1). 
Austria, Bulgaria, Cyprus and Liechtenstein did not respond to the survey and are not included in the analysis. At 
the time of the survey, Croatia was not part of the EU/EEA. 
All country-specific responses refer to the situation in the entire country, with the exception of Ireland where the 
responses on syphilis only refer to Dublin. Northern Ireland participated in the pilot project; the Northern Irish 
results were later merged with those of other UK countries. If there were differences in results between the four 
UK countries are always indicated. 
3.2 Antenatal screening programmes: organisation and 
integration  
With the exception of Romania, all responding EU/EEA countries confirmed that they have released a national 
guidance or recommendations on antenatal care, including pregnancy, antenatal, neonatal and post-natal care 
(Table 1). In Romania, in the absence of a comprehensive national guidance, various professional bodies have 
issued recommendations on antenatal care.  
Furthermore, 25 of 26 responding countries (all but Hungary) confirmed that they have a national guidance 
document, recommendations or a strategy for antenatal screening of infectious diseases. Antenatal screening is 
recommended for HIV in 24 countries (not in Hungary and Slovenia), for HBV in 23 countries (not in Lithuania, 
Norway and Romania), for syphilis in all 26 responding countries, and for rubella susceptibility in 17 countries (not 
in Denmark, Estonia, Finland, Hungary, Latvia, Lithuania, the Netherlands, Romania and Slovenia) (Table 1). 
In the vast majority of EU/EEA countries, screening of infectious diseases is integrated into overall antenatal care. 
Luxembourg does not integrate screening for any of the four infectious diseases covered by this report.  
Table 1. Availability of national guidance/recommendations/strategy for antenatal care/antenatal 
screening for HIV, HBV, syphilis and rubella susceptibility in the EU/EEA, 2013  
Country 
National guidance 
for antenatal care 
National guidance 
for antenatal 
screening of 
infections 
National screening recommended for 
HIV HBV Syphilis Rubella susceptibility 
Belgium Yes Yes Yes Yes Yes Yes 
Czech Republic Yes Yes Yes Yes Yes No  
Denmark Yes Yes Yes Yes Yes No 
Estonia Yes Yes Yes Yes Yes No 
Finland Yes Yes Yes Yes Yes No 
France Yes Yes Yes Yes Yes Yes 
Germany Yes Yes Yes Yes Yes No 
Greece Yes Yes Yes Yes Yes Yes 
Hungary Yes No No Yes Yes No 
Iceland Yes Yes Yes Yes Yes Yes 
Ireland Yes Yes Yes Yes Yes Yes 
Italy Yes Yes Yes Yes Yes Yes 
Latvia Yes Yes Yes Yes Yes No 
Lithuania Yes Yes Yes No Yes No 
Luxembourg Yes Yes Yes † Yes † Yes† Yes † 
Malta Yes Yes Yes Yes Yes Yes 
Netherlands Yes Yes Yes No Yes No 
Norway Yes Yes Yes Yes Yes Yes 
Poland Yes Yes Yes Yes Yes Yes 
Portugal Yes Yes Yes Yes Yes Yes 
Romania No± Yes Yes No Yes No 
Slovakia Yes Yes Yes Yes Yes Yes 
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Country 
National guidance 
for antenatal care 
National guidance 
for antenatal 
screening of 
infections 
National screening recommended for 
HIV HBV Syphilis Rubella susceptibility 
Slovenia Yes Yes No Yes Yes No 
Spain Yes Yes Yes Yes Yes Yes 
Sweden Yes Yes Yes Yes Yes No 
UK Yes Yes Yes Yes Yes Yes 
† Screening not integrated in overall antenatal care 
± Romania: no national guidance on antenatal care exists, but separate recommendations have been issued by various 
professional bodies.  
3.3 Antenatal HIV screening: survey results  
Responses to the questionnaire on antenatal HIV screening were received from 25/26 countries, with Portugal the 
one country that did not fill in the HIV-specific questionnaire. Instead, Portugal provided information on the 
implementation of HIV screening in the general questionnaire.  
Implementation of antenatal HIV screening 
Antenatal screening for HIV is implemented in 24/26 (92%) countries (Table 1). Hungary and Slovenia do not offer 
national antenatal screening for HIV; Slovenia stated that the primary reason for not offering antenatal HIV 
screenings was the fact that HIV epidemiology did not support the need for a national screening programme; 
Hungary cited limited resources.  
Funding of antenatal HIV screening 
Antenatal screening for HIV is publicly funded (and offered free of charge) in 15/25 (60%) countries. A further 
eight countries (32%) offer antenatal HIV screening through various health insurance schemes (Table 2).  
Table 2. Financing of antenatal HIV screening, EU/EEA, 2013  
Publicly funded Health insurance No HIV screening 
n=15 n=8 n=2 
DK, FI, FR, IS, IE, IT, LV, LT, MT, NL, NO, RO, ES, SE, UK BE, CZ, EE, DE, GR, LU, PL*, SK HU†, SI†† 
 † HIV screening not provided due to limited resources 
†† Epidemiology does not support the need for HIV screening  
* Poland reported that antenatal screening for uninsured pregnant women was funded through the public health budget. 
Country names use ISO 3166-1 country codes 
Data collection, storage and analysis 
Data on antenatal screening for HIV are collected, stored and analysed at a national level in 11 countries (Czech 
Republic, Denmark, Estonia, Finland, France, Ireland, Lithuania, the Netherlands, Romania, Slovakia and the UK).  
Monitoring or evaluation of the effectiveness of antenatal screening programmes for HIV was reported by Denmark  
[27], Finland, [28] France, [29] Ireland, Italy, the Netherlands [24,30] Romania  [31], Slovakia and the UK.  
Strategies for antenatal HIV screening 
The most common strategy (15/24) of antenatal screening for HIV in EU/EEA countries is opt-out screening, where 
pregnant women are tested as part of routine antenatal care unless they explicitly decline. Opt-in screening is the 
chosen strategy in six countries (as well as in Northern Ireland (UK)), where pregnant women are offered testing 
and must provide explicit consent. The Czech Republic, Slovakia and Spain reported universal screening for HIV 
with systematic testing of all pregnant women (Figure 4). Romania and Slovenia reported that they operated 
targeted antenatal HIV screening among women who inject drugs.  
  
 
 
 
 
Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA  TECHNICAL REPORT 
 
 
 
14 
 
 
 
Figure 4. Antenatal HIV screening strategies, EU/EEA, 2013 survey 
 
Note: Opt-in antenatal screening for HIV is implemented in Northern Ireland (UK).  
Laboratory methods for antenatal HIV screening  
There are three main categories of tests used for antenatal HIV screening in the EU/EEA: antibody tests, 
combination tests, and nucleic acid amplification tests (NAATs). While combination tests detect both HIV antibody 
and antigen, NAATs detect the genetic material of the virus. Both test types are able to detect HIV infections 
relatively early compared to antibody tests. However, NAATs allow for an even earlier detection of infection. NAATs, 
however, are more expensive and technically more demanding [32]. 
Eighteen of 23 countries reported that they use an HIV combination test for antenatal screening; Belgium and 
Slovenia reported the use of NAATs for antenatal screening (Figure 5).  
Figure 5. Tests used for antenatal HIV screening, EU/EEA, 2013 survey 
 
* If the mother’s HIV status is unknown, rapid tests are used at delivery. 
Timing of screening and testing coverage 
Antenatal screening for HIV is recommended during the first trimester of pregnancy in 21/23 EU/EEA countries. In 
Ireland and Malta, testing is done at the time of booking antenatal care (Table 3).  
In addition, Estonia, Lithuania, Romania, Slovakia and Spain reported recommendations on repeated HIV testing 
during the third trimester of pregnancy. In France, Greece, Ireland, Italy and Norway only women belonging to 
nationally defined risk groups are re-tested later in pregnancy. The risk groups tested in Ireland include: pregnant 
women that are active injecting drug users, pregnant women with known HIV infected partner, pregnant women 
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Nucleic acid amplification test (NAAT)
Rapid point of care antibody test (blood or saliva)
Antibody testing
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whose partner is from a high-prevalence country, or pregnant women whose partner is at risk for HIV infection and 
of unknown HIV status.  
For women not tested earlier in pregnancy, antenatal screening for HIV is recommended at delivery in Denmark, 
France, Germany, Greece, Ireland, Latvia, Romania, Spain and the UK. 
Screening coverage during the first trimester was reported to be 95% or higher in almost half (8/15) of the 
countries providing data (Table 3). Iceland reported the lowest coverage (50%), ahead of Romania which reported 
60% coverage.  
Overall coverage – the percentage of women tested at least once during pregnancy – was high among respondent 
countries, with the majority (12/18) estimating 95% or higher. Iceland provided the lowest overall coverage 
estimate at 50% (Table 3).  
Table 3. Implementation of antenatal HIV screening in the EU/EEA and coverage data for 2011 (or 
most recent year available), as reported by survey responders 
Country 
Antenatal screening 
during 
1st trimester 
Antenatal screening 
coverage 
1st trimester† 
Repeated 
screening 
Antenatal screening 
coverage overall†† 
Belgium Yes   73%–78%± 
Czech Republic Yes 80%  >99% 
Denmark Yes (D)   98% 
Estonia Yes >80% 3rd trimester >80% 
Finland Yes 98%  98% 
France Yes (D) 99% At delivery, in risk groups 99% 
Germany Yes (D) 87%–93%  87% - 93% 
Greece Yes (D)  3rd trimester, in risk groups  
Iceland Yes 50%  50% 
Ireland Yes¥ (D)  3rd trimester, in risk groups  98.6% 
Italy Yes 90% At delivery, in risk groups 90% 
Latvia Yes (D) 88%–89%   
Lithuania Yes  3rd trimester 93% 
Luxembourg Yes 98%  100% 
Malta Yes¥   ~100% 
Netherlands Yes 99.8%  99.8% 
Norway Yes 95% At delivery, in risk groups 95% 
Poland Yes *   
Romania Yes (D) ~60% 3rd trimester  
Slovakia Yes 98% 3rd trimester 99% 
Spain Yes (D)  3rd trimester ~100% 
Sweden Yes >95%   
UK Yes (D) 95%  >95% 
† Country data for 2011 or for the most recent year; if no monitoring data were available, survey responders were invited to 
provide estimates 
†† Percentage of pregnant women tested at least once  
¥ At time of booking of antenatal care 
D Testing at delivery if not done earlier 
± Belgium: higher coverage value refers to pregnant women with high-risk profile (the risk is based on age – under 16 or above 
40 years of age, socio-economic status, and medical comorbidities)  
* Poland reported a 66.6% coverage in Mazowieckie region in 2013, based on a sample of 1 111 pregnant women  
Note: Hungary and Slovenia do not implement national antenatal HIV screening. In Northern Ireland, HIV screening is repeated 
at delivery, with 98.5% of women tested at least once during pregnancy. 
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HIV diagnosis during pregnancy 
Fifteen of 21 countries reported that they were able to distinguish between HIV infections that were known before 
pregnancy and HIV infections newly diagnosed during the current pregnancy (Table 4). The percentage of 
pregnant women newly diagnosed with HIV during their current pregnancy ranged between 0% and 63% and was 
over 30% in eight of the 13 countries where this estimation was possible (Table 4). The survey did not include 
additional questions on the procedures used.  
Table 4. HIV-positive pregnant women and timing of HIV diagnosis in relation to current pregnancy, 
EU/EEA countries 
Country 
Number of HIV-positive 
pregnant women 
(S) 
Ability to distinguish between HIV 
infections diagnosed during 
current pregnancy vs. infection 
diagnosed before pregnancy 
Pregnant women diagnosed during current 
pregnancy 
 
N 
(S) 
% 
(C) 
Belgium 250 Yes NR  
Czech Republic 8 Yes 3 38% 
Denmark 39 Yes 12 31% 
Estonia 20 No   
Finland 22 Yes 9 41% 
France 1500 Yes ~200 13% 
Germany  No   
Greece 21 Yes 10 48% 
Iceland 2 Yes 0 0% 
Ireland 109 Yes 17 16% 
Latvia 25 No   
Lithuania 8 Yes 5 63% 
Luxembourg 14 Yes 7 50% 
Malta 6 No   
Netherlands 89 Yes  *40% 
Norway 11 Yes   
Poland 67 No   
Romania 259 Yes 95 37% 
Slovakia 2 Yes 0 0% 
Slovenia 0    
Spain 0  0  
Sweden 13 No   
UK 1114 Yes 223 20% 
(S) Survey data provided by survey responders for 2011 or for the most recent year 
(C) Calculated 
* Responder’s estimate 
Note: Numbers in italics represent 2012 data or, in the case of Poland, 2013 data. 
Vertical transmission of HIV 
In 2013, 19 countries reported a total of 91 cases of MTCT in persons born in the reporting country (data retrieved 
from TESSy). Ten countries reported zero MTCT. The HIV MTCT case rate per 100 000 live births ranged between 
0.7 in Germany and 43.7 in Latvia (Annex 2). When the age of reported cases was restricted to less than two 
years, the total number of MTCT cases in persons born in the reporting country was 53, and the MTCT rate ranged 
between 0.3 (Germany and the UK) and 29.1 (Latvia) (Annex 2).  
Testing of children born to HIV-positive mothers 
All 25 responding countries recommend HIV testing of children born to an HIV-positive mother. NAATs are used for 
diagnosis in 23/25 responding countries; HIV combination tests are used in Hungary and Spain. Eleven countries 
(Czech Republic, Finland, Estonia, Ireland, Malta, the Netherlands, Norway, Poland, Romania, Slovakia and 
Slovenia) use both HIV combination tests and NAATs. 
Belgium, Hungary, Italy and Spain recommend that children should be tested once, at birth. In all other EU/EEA 
countries, children are tested more than once (Table 5). The estimated percentage of children tested at least once 
varied between 91% and 100% in the responding countries. 
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Table 5. Children born to HIV-positive mothers: age at last HIV test, EU/EEA, 2013  
At birth 
n=4 
3–6 
months 
n=6 
12–18 
months 
n=13 
20–24  
months 
n=2 
BE, HU, IT, ES DK, IE, IS, FR, GR, LU, NO CZ, EE, FI, DE, IS, LV, LT, MT, NL, 
PL, RO, SI, UK 
SE, SK 
Note: Countries in bold only use HIV combination tests for diagnosis; all other countries use NAATs alone or in association with 
HIV combination tests (countries in italic). 
HIV: referral and retention in care  
HIV-positive pregnant women are referred to specialised HIV treatment and care services in 21 of the 24 countries 
(not in Finland, France and the UK). Sexually transmitted infection (STI)/genito-urinary medicine (GUM) clinics are 
the primary places for referral in Finland and the UK. A multi-disciplinary team was reported to be involved in the 
HIV care for pregnant women in France, Finland and the UK. To a lesser extent, HIV-positive pregnant women are 
referred to gynaecologists/obstetricians (Iceland, Italy, Latvia, Norway, Slovenia and Spain). 
Data on the proportion of pregnant women with HIV who receive antiretroviral treatment (ART) or prophylaxis 
during pregnancy are available in six countries (Finland, Greece, Luxembourg, Malta, Slovakia and the UK). In 
these six countries – and in a further 12 countries with estimated data – between 95% and 100% of pregnant 
women with HIV are on ART.  
In the majority of countries, the infection status of the newborn/infant is monitored through collaboration between 
HIV clinics/treatment centres and neonatologists/paediatricians (Belgium, Denmark, France, Iceland, Italy, Latvia, 
Poland, Slovakia, Slovenia, Spain and the UK). Monitoring via HIV treatment centres/clinics occurs in the Czech 
Republic, Estonia, Hungary, Ireland and Lithuania and by neonatologists/paediatricians in Germany, Luxembourg, 
Malta, Norway and Northern Ireland (UK). Specialised HIV treatment centres for children provide care in the 
Netherlands, and in Romania, children are monitored in infectious disease hospitals/wards that specialise in HIV. 
Finland, Greece and Ireland have paediatric infectious disease clinics/centres. 
Data on the proportion of newborn children who go on to be enrolled in HIV care are reported by only a few 
countries (Czech Republic, Estonia, Greece, Iceland, Lithuania, Malta, Poland and Romania). Several countries 
reported that 98–100% of all children of HIV-positive pregnant women receive HIV care (Belgium, Denmark, 
France, Germany, Italy, the Netherlands, Norway, Slovenia, Spain and the UK – reported and estimated data).  
Treatment/prophylaxis of mother and child  
Antiretroviral therapy (ART) for HIV-positive pregnant women (who have not been in treatment before the 
pregnancy) is implemented as a combination of three drugs in 23/24 countries. In the Czech Republic, the 
treatment is implemented as a combination of two drugs. Monotherapy was reported to be considered in some 
cases in Ireland and the UK. In Latvia all options are considered. The coverage of ART in HIV-positive pregnant 
women was estimated at between 95 and 100% in 6/23 countries (Finland, Greece, Luxembourg, Malta, Slovakia 
and the UK).  
Caesarean section is recommended to HIV-positive mothers in 8/25 countries (Czech Republic, Italy, Latvia, 
Lithuania, Poland, Romania, Slovakia and Slovenia) while in 14/25 countries (Belgium, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Iceland, Ireland, Luxembourg, Spain, Sweden and the UK), this option depends 
on the mother’s viral load. Caesarean section is not recommended in Malta, the Netherlands and Norway.  
All responding countries recommend that HIV-positive mothers refrain from breastfeeding. 
Between 90 and 100% of children born to HIV-positive mothers receive antiretroviral prophylaxis in 9/23 reporting 
countries (Estonia, Greece, Iceland, Italy, Lithuania, Luxembourg, Malta, Slovakia and the UK). The number of 
drugs used for HIV prophylaxis of children varies between countries; national guidelines can recommend one or 
more drugs based on a case-based assessment of the risk of MTCT (Table 6). 
Table 6. The number of drugs used for the HIV prophylaxis of the child, EU/EEA, 2013  
One drug* One drug Two drugs Three drugs 
BE, EE, FR, DE, GR, IE, LV, MT, PL, SI, 
UK 
  
CZ, FI, IS, IT, LT, LU, 
SE 
  
DE, GR, IE, NL, 
RO 
  
BE, DK, EE, FR, DE, GR, IE, LV, MT, NL, NO, PL, SK, ES, 
UK 
* Dependent on mother’s treatment and viral load 
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Populations at risk of mother-to-child transmission of HIV and 
challenges for effective antenatal screening 
The most commonly recognised risk groups reported as not being reached by antenatal HIV screening programmes 
in the responding countries were: migrants from high-prevalence areas outside the EU, pregnant women 
presenting late for screening, pregnant women who inject drugs, mobile populations within the EU, women whose 
partners belong to risk groups (including migrants from high-prevalence areas, PWIDs, mobile populations) 
(Figure 6).  
The two most common challenges for implementing effective antenatal screening policies for HIV were: insufficient 
capacity for reaching risk groups and low-quality national data (lack or incomplete data) (Figure 6). 
Figure 6. Population groups reported as not being effectively reached by antenatal HIV screening 
programmes and vulnerable to MTCT of HIV, EU/EEA, 2013  
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Women with multiple sexual partners
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People who inject drugs 
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Figure 7. Challenges for the implementation of effective antenatal HIV screening policies, 
EU/EEA, 2013 
 
3.4 Antenatal HBV screening: survey results  
Responses to the HBV antenatal screening questionnaire were received from 22/26 countries, - Portugal, Slovenia 
and Slovakia did not respond; Belgium partially responded in the validation phase.  
Implementation of antenatal HBV screening 
Antenatal screening for HBV is implemented in 23/26 (88%) countries. Lithuania, Norway and Romania do not 
implement national antenatal HBV screening. Lithuania and Romania state limited resources as the main reason for 
not offering antenatal HBV screening, while Norway cites a low HBV incidence that does not warrant universal 
antenatal HBV screening.  
Funding of antenatal HBV screening 
HBV antenatal screening is publicly funded (and free of charge) in 14/20 countries; another six countries offer 
antenatal HBV screening through health insurance schemes (Table 7).  
Table 7. Financing of HBV antenatal screening, EU/EEA, 2013 
Publicly funded 
n=14 
Health insurance 
n=6 
DK, FI, FR, HU, IE, IS, IT, LV, MT, NL, PL, ES, SE, UK  BE, CZ, EE, DE, GR, LU 
Information not provided by Portugal, Slovenia and Slovakia.  
Data collection, storage and analysis 
Collection, storage and analysis of data on antenatal HBV screening occur at a national level in eight responding 
countries (Czech Republic, Denmark, Finland, France, Malta, the Netherlands, Slovakia and the UK).  
Monitoring or evaluation of the effectiveness of antenatal screening programmes for HBV has been performed in 
Denmark  [27], Finland  [28], France  [33], Italy  [34] ,the Netherlands [24,30], Slovakia and the UK.  
Vaccination policies and coverage  
HBV vaccination is part of the national childhood vaccination programme in 20 of the 26 responding EU/EEA 
countries. Coverage varies from 74% to 99%. Denmark, Finland, Iceland, Norway, Sweden and the UK offer 
vaccine to babies born to HBV-infected mothers or mothers from risk groups.  
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All but one (Slovakia) of the 26 responding countries offer one dose of HBV vaccine at birth (within the first 12 to 
24 hours). This is based either on a general recommendation or because these children were born to HBV-infected 
mothers or to mothers from risk groups.  
In addition to childhood vaccination, many countries implement vaccination programmes in selected population 
groups at risk, e.g. healthcare workers, people who inject drugs, sex workers and migrants (Figure 8). Other risk 
groups mentioned were: close contacts of HBV carriers and confirmed cases, travellers to high-prevalence areas, 
prison workers, prisoners, families adopting from endemic countries, security and police forces, patients with 
chronic diseases and mobile populations.  
Figure 8. HBV vaccination programmes in population groups at risk, EU/EEA, 2013  
 
 
 
Strategies for antenatal HBV screening  
The most common (14/23, 61%) antenatal HBV screening strategy in the EU/EEA is opt-out screening, followed by 
universal screening (7/23, 30%). Estonia and Luxembourg use opt-in screening. In the absence of a national 
programme, antenatal HBV testing is offered to selected pregnant women based on a doctor’s/midwife’s 
assessment in Norway and to women who inject drugs in Romania (Figure 9).  
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Figure 9. Antenatal HBV screening strategies, EU/EEA, 2013 
 
Note: Opt-in antenatal HBV screening is implemented in Northern Ireland (UK); testing is offered to selected pregnant women in 
Romania (PWID) and in Norway (based on clinician’s assessment) 
Laboratory methods for antenatal HBV screening  
HBsAg testing is used in all the 20 countries that provided information. In addition, three countries (Estonia, 
Iceland and Romania) reported HBeAg testing. Belgium, Luxembourg, Malta and Sweden use anti-HBc testing 
(Figure 10).  
Figure 10. Tests used for antenatal HBV screening, EU/EEA, 2013  
 
Timing of screening and testing coverage 
Antenatal HBV screening is recommended during the first trimester of pregnancy in 14/20 of the responding 
countries. In France, screening is recommended at six months of pregnancy; in Estonia, Germany, Iceland, Italy 
and Poland it is recommended during the third trimester (Table 8). 
The Czech Republic recommends repeated HBV testing during the third trimester of pregnancy.  
Germany, Greece, Latvia, Poland, Spain and Northern Ireland (UK) recommend HBV screening at delivery, if it was 
not performed during pregnancy. 
The percentage of women tested at least once during pregnancy was estimated at over 95% in 8 of 13 of the 
responding countries. Estonia and Hungary estimated the coverage to be around 90%, while Iceland estimated 
that only 50% of the pregnant women are tested (Table 8).  
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Table 8. Implementation of antenatal HBV screening in the EU/EEA and coverage data for 2011 (or 
most recent year available), as reported by survey responders  
Country First screening test recommended Pregnant women tested at least once  
Belgium 1st trimester 80%–85%± 
Czech Republic 1st trimester 99.8% 
Denmark 1st trimester 99% 
Estonia 3rd trimester >90% 
Finland 1st trimester 98% 
France 6 months ~87.5% (2010) 
Germany 3rd trimester†  
Greece 1st trimester†  
Hungary 1st trimester 90% 
Iceland 3rd trimester 50% 
Ireland 1st trimester >95% 
Italy 3rd trimester 97.7% (2008–2009) 
Latvia 1st trimester  
Lithuania -  
Luxembourg 1st trimester ~95% 
Malta 1st trimester‡ 100% 
Netherlands 1st trimester 100% 
Poland 3rd trimester†  
Romania -  
Spain 1st trimester†  
Sweden 1st trimester  
UK  1st trimester  
† Screening offered at delivery if note performed earlier 
‡ At time of booking of antenatal care 
± Belgium: higher coverage value refers to pregnant women with high-risk profile (the risk is based on age – under 16 or above 
40 years of age, socio-economic status, and medical comorbidities)  
 
Northern Ireland offers screening during the first trimester and at delivery if not done earlier. 98.5% of pregnant women were 
tested at least once for HBV. 
Note: Lithuania, Norway and Romania do not offer national HBV antenatal screening.  
HBV diagnosis during pregnancy 
Nine of 22 countries reported that they were able to distinguish between HBV infections that were known before 
pregnancy and HBV infections newly diagnosed during the current pregnancy. This distinction is possible in the 
Czech Republic, Denmark, Hungary, Latvia, Norway, Romania, Spain, Sweden and the UK. In Finland, this is 
possible if the pregnant woman was tested during an earlier pregnancy. The percentage of newly diagnosed 
infections ranged from 0.5% in the Czech Republic to 100% in Denmark. In Finland it was 54%, 55% in England 
(UK), 73% in Estonia, and 97% in Latvia. 
Vertical transmission of HBV 
Six cases of MTCT of HBV were reported in children below the age of two. All six cases were identified as ‘non-
imported’ (TESSy data, 2013): Germany (1), Ireland (1), Latvia (2), Romania (1) and Slovakia (1). Another six HBV 
infections in 2013 were reported – also in children under the age of two – as ‘non-imported’ but with an ‘unknown’ 
transmission mode: Austria (2), Spain (1) and Romania (3). The relevance of these cases for the performance of 
antenatal screening is unclear.  
 
 
Testing of children born to HBV-infected mothers is recommended in 18/20 countries, the exceptions being Italy 
and Poland (Table 9). In Poland, although testing is not officially recommended, it is routinely offered at 9 to 13 
months of age by primary care practitioners.  
Testing of children born to HBV-positive mothers [35] 
Maternal HBeAb can be transmitted through the placenta. However, in the absence of HBV viraemia, most 
infants who are HBeAg positive at birth will lose the HBeAg by the time they reach six to 12 months of age. 
Therefore, the most important predictor of infant infection and immunoprophylaxis failure is detectable HBV 
DNA in the infant’s serum at birth. Anti-HBc testing of infants born to HBV-infected mothers is not 
recommended, as passively acquired maternal anti-HBc may be detected up to the age of 24 months. 
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HBsAg testing is used for the diagnosis of HBV in children born to HBV-positive mothers in all countries that 
perform this testing; eight of which also use NAATs (Table 10).  
Table 9. HBV testing among children born to HBV-infected mothers and age at the time of the last 
test, EU/EEA, 2013  
Number of HBV tests given to child Age of child at last test <9 months Age of child at last test >9 months 
1 test EE, FR, RO DK, ES, FI, GR, HU, IE, MT, NL, UK 
2 tests DE, IS LV, NO, SE 
>2 LU  
 
Table 10. Diagnostic tests used to detect HBV infection in children born to HBV-positive mothers, 
EU/EEA, 2013  
HBsAg NAAT Anti-HBc Anti-HBs HBeAg 
CZ, EE, FI, FR, DE, GR, HU, IS, IE, LV, LU, MT, 
NL, NO, PL, RO, ES, SE, UK 
CZ, EE, FI, GR, LV, NO, SE, UK† CZ, DE, IE, NO FR, IE, DE, LU, NL DE 
† Northern Ireland  
Confirmatory testing of seroconversion after vaccination (anti-HBs) of children born to HBV-positive mothers is 
done in 15 countries (Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Luxembourg, 
Malta, the Netherlands, Norway, Spain and Sweden); confirmatory testing is not performed in the Czech Republic, 
Estonia, Poland, Romania and the UK. Ireland reported very low implementation rates of existing recommendations 
on follow-up testing.  
HBV: referral and retention in care 
National data about the proportion of pregnant women with positive HBV results that were referred to specialist 
care were only available from Malta. Denmark, Finland and Northern Ireland (UK) gave estimates: 60%, <5% and 
100%, respectively.  
HBV-infected pregnant women are referred for care to hepatologists/gastroenterologists in 13/21 countries (Czech 
Republic, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Luxembourg, the Netherlands, 
Poland and the UK). Women in Iceland can also be referred to a gynaecologist/obstetrician and/or a STI/GUM 
clinic; in Czech Republic and Poland to a gynaecologist/obstetrician; and in Luxembourg to a STI/GUM clinic.  
In Denmark, Italy, Romania and Sweden pregnant women are referred to an infectious disease specialist/unit; in 
Finland and Malta to STI/GUM clinic; in Norway women are provided care by a primary care practitioner and can be 
referred to a gynaecologist/obstetrician.  
The infection status of the newborn/infant born to an HBV-positive mother is monitored by paediatricians in the 
majority (16/22) of countries. In Denmark, Estonia, Hungary, the Netherlands and the UK, monitoring is done in 
primary care. There is no child monitoring in Luxembourg. A specialist in hepatology is involved in the Czech 
Republic, France, Latvia and Poland. In Ireland, Latvia and the UK, the primary care provider is supported by a 
hepatologist and a paediatrician.  
 
 
The prevention of MTCT for children born to HBV-positive mothers is implemented as a combination of vaccination 
(first dose administered within 24 hours of birth) and administration of HBV immunoglobulin in 18/21 responding 
countries. In Estonia, Latvia and Romania only vaccination is used. Norway and Sweden use antiviral prophylaxis 
(therapy administered to the mother) in certain case-based circumstances, in addition to vaccination and 
immunoglobulin.  
Treatment/prophylaxis for the child  [36] 
WHO guidelines recommend that infants should receive a first dose of HBV vaccine as soon as possible after 
birth, preferably within 24 hours of birth, followed by completion of the HBV vaccine series during the first year of 
life. Administration of HBV immunoglobulin in conjunction with HBV vaccination may be of benefit for infants born 
to mothers who are both HBsAg and HBeAg positive. No recommendation for the routine use of antiviral therapy 
to prevent HBV MTCT has been formulated.  
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Populations at risk of mother-to-child transmission of HBV and 
challenges for effective antenatal screening  
According to the responding countries, the following population groups were at risk of being missed by antenatal 
HBV screening programmes: migrants from high-prevalence areas outside the EU, women presenting late in 
pregnancy, pregnant women who inject drugs, and mobile populations (Figure 11).  
The three most common challenges for implementing effective antenatal screening policies for HBV were: lack of 
reporting and collection of data at the national level, insufficient capacity for reaching populations at risk and a lack 
of resources (Figure 12).  
Figure 11. Population groups at risk of not being (entirely/effectively) reached by antenatal HBV 
screening programmes and still vulnerable to MTCT of HBV, EU/EEA, 2013  
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Figure 12. Challenges for the implementation of effective antenatal screening policies for HBV, 
EU/EEA, 2013  
  
3.5 Antenatal syphilis screening: survey results  
Responses to the syphilis antenatal screening questionnaire were received from 24/26 countries; Portugal and 
Poland did not respond.  
Implementation of antenatal screening for syphilis 
Antenatal screening for syphilis is implemented in all 24 responding countries: Belgium, the Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Malta, the Netherlands, Norway, Romania, Slovakia, Slovenia, Spain, Sweden and the UK.  
Funding of antenatal screening for syphilis 
Antenatal syphilis screening is publicly funded (free of charge) in 15/24 countries. Another 9/24 countries offer 
antenatal syphilis screening through health insurance schemes (Table 11).  
Table 11. Financing of antenatal screening for syphilis, EU/EEA, 2013 survey 
Publicly funded 
n=15 
Health insurance 
n=9 
DK, FI, HU, IS, IE, IT, LV, LT, MT, NL, NO, RO, ES, SE, UK BE, CZ, EE, FR, DE, GR, LU, SK, SI 
Data collection, storage and analysis 
Data on antenatal screening for syphilis are collected, stored and analysed at the national level in eight countries: 
Denmark, Finland, Lithuania, Malta, the Netherlands, Romania, Slovakia and the UK.  
Monitoring or evaluation of the effectiveness of antenatal screening programmes for syphilis have been performed 
in Denmark [30], Finland [28], Italy, the Netherlands [24], Slovakia and the UK.  
Strategies for antenatal syphilis screening  
Data on the type of screening strategy were available for 26 countries, including Portugal and Poland. The most 
common strategy (16/26, 62%) of antenatal screening for syphilis in EU/EEA countries is an opt-out strategy, 
followed by universal screening (7/26, 27%). Estonia, Lithuania and Luxembourg reported opt-in screening for 
syphilis (Figure 13). Antenatal syphilis screening targeting sex workers on an irregular basis was reported by 
Romania.  
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Figure 13. Syphilis antenatal screening strategies, EU/EEA, 2013  
 
Note: Opt-in antenatal screening for syphilis is implemented in Northern Ireland (UK)  
 
 
Both treponemal and non-treponemal tests are in use for the antenatal screening of syphilis in most EU/EEA 
countries (15/24). In Iceland, Norway and Spain only non-specific treponemal tests are used. In Belgium, Estonia 
and Germany only specific treponemal tests are in use. IgM/IgG enzyme immunoassays are in use in Finland, Malta 
and Slovakia (Figure 14). Testing methods in Denmark are selected by individual laboratories.  
Figure 14. Tests used for antenatal screening of syphilis, EU/EEA, 2013  
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Laboratory methods for antenatal syphilis screening  
Antenatal screening for syphilis is carried out with specific and nonspecific treponemal tests (specific: 
Treponema pallidum particle agglutination test (TPPA), Treponema pallidum haemagglutination, enzyme 
immunoassay vs. nonspecific: rapid plasma reagin and venereal disease research laboratory).  
Traditionally, non-treponemal tests are used for syphilis screening; however, during the last decade, non-
treponemal tests have been replaced by highly sensitive and specific enzyme immunoassays.  
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Antenatal screening for syphilis is recommended during the first trimester of pregnancy in 22/24 countries that 
provided this information. In Malta, testing is done at the time of booking antenatal care. Syphilis screening is 
recommended during the second trimester of pregnancy in Hungary. 
In addition, the Czech Republic, Estonia, Latvia, Lithuania, Romania, Slovakia and Spain reported having 
recommendations on repeated syphilis testing during the third trimester of pregnancy. In Belgium, France and 
Italy, women from risk groups are re-tested during the third trimester (Table 12).  
Denmark, Estonia, Latvia, Lithuania, Spain and Romania mentioned that antenatal screening for syphilis is 
recommended at delivery if not already done earlier in pregnancy.  
The estimated coverage of syphilis screening during the first trimester of pregnancy was over 95% in four 
countries (Finland, Ireland, Netherlands, Sweden) and between 80% and 95% in another nine (Czech Republic, 
Estonia, Germany, Iceland, Latvia, Luxembourg, Norway, Slovakia, Slovenia) (Table 12).  
The percentage of women tested at least once during pregnancy was estimated as 95% or higher in 14 of 18 
responding countries. Hungary estimated the coverage at between 90% and 100%, Slovenia and Iceland 
estimated 90%, and Belgium cited a coverage of between 63% and 74%.  
Table 12. Implementation of antenatal syphilis screening in the EU/EEA and coverage data for 2011 
(or most recent year available), as reported by survey responders 
Country Antenatal 
screening during  
1st trimester 
Antenatal screening 
coverage  
1st trimester 
Repeated  
screening 
Antenatal screening 
coverage overall 
 
Belgium Yes  3rd trimester, risk groups 63%–74%± 
Czech Republic Yes 80% 3rd trimester 99.8% 
Denmark Yes (D)   98% 
Estonia Yes (D) >90% 3rd trimester >95% 
Finland Yes 98%  98% 
France Yes  3rd trimester, risk groups >95% 
Germany Yes 95%   
Greece Yes  3rd trimester  
Hungary No (16th week)   90%–100% 
Iceland Yes 90%  90% 
Ireland Yes 98%  95% 
Italy Yes  3rd trimester, risk groups  
Latvia Yes (D) 88–89% 3rd trimester  98% 
Lithuania Yes (D)  3rd trimester  
Luxembourg Yes 95%  95% 
Malta *   100% 
Netherlands Yes >95%  >99% 
Norway Yes 95%  95% 
Romania Yes (D)  3rd trimester  
Slovakia Yes 95% 3rd trimester 99% 
Slovenia Yes >80%  >90% 
Spain Yes (D)  3rd trimester ~100% 
Sweden Yes >98%   
UK**  Yes    97% 
(D) Tested at delivery if not tested earlier 
± Belgium: higher coverage value refers to pregnant women with high-risk profile (the risk is based on age – under 16 or above 
40 years of age, socio-economic status, and medical comorbidities)  
* At time of booking of antenatal care 
** England only. In Northern Ireland, syphilis screening is recommended during the 1st trimester and at delivery if not tested 
earlier; overall coverage 98.5%.  
Timing of screening and testing coverage  [37] 
The timing of antenatal interventions has a significant impact on the risk of becoming infected with syphilis. 
Women who were tested and received appropriate treatment during the first two trimesters of pregnancy were 
2.24 times (95% CI 1.28, 3.93) more likely to have a healthy baby than those receiving syphilis treatment during 
their third trimester. 
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Policies for partner notification  
In 21/24 EU/EEA countries, there is an official policy for partner tracing and treatment of all sexual contacts of a 
syphilis-positive pregnant woman. There is no such official policy for partner tracing in Belgium, France and 
Germany. 
Vertical transmission of syphilis 
In 2013, 64 cases of congenital syphilis were notified by nine of the 21 countries that reported data to TESSy. The 
congenital syphilis rate per 100 000 live births ranged between 0.3 in Germany and 40.6 in Bulgaria. Twelve 
countries reported no congenital syphilis cases in 2013 (Annex 2). 
 
 
All 24 responding countries recommend testing of children born to mothers diagnosed with syphilis, except for 
Finland, where testing is not done if the mother has been treated during pregnancy. Most of the responding 
countries use both non-specific and specific treponemal tests in the diagnosis of congenital syphilis. Belgium, 
France, Hungary and Norway also use nucleic acid testing or a direct antigen detection method for diagnostics. The 
number of tests and the age of the child at testing varies between countries (Table 13). In the UK, children are 
tested repeatedly, beginning with birth and then during follow-ups. Follow-ups depend on factors such as the 
presence of symptoms in the mother or the baby or the type of treatment that the mother received. 
Table 13. Syphilis testing among children born to infected mothers and age at the time of the last 
test, EU/EEA, 2013  
Number of syphilis tests given to the child 
Age of child at time of last test 
At birth 6-12 months 
>12 and 
<24 months 
24 months 
Until 
negative or 
fourfold 
decline 
On an 
individual 
basis 
No age 
given 
1 test ES NL RO     
2 tests  IT, LU, MT FR  MT   
2+ tests    SK, SI   NO 
3 tests  IS IE     
3+ tests    HU    
5 tests       FI* 
7 tests    CZ    
No number specified     DK, EE, GR DE, LV, LT UK 
Countries in bold use NAATs or a direct antigen detection method for diagnostics. 
* If the mother was not treated during pregnancy  
Syphilis: referral and retention in care 
Pregnant women diagnosed with syphilis are referred to STI/GUM clinics in 13/24 countries (Denmark, Finland, 
Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Malta, Norway, Romania, Sweden and the UK) and to a 
gynaecologist/obstetrician in Estonia, Germany, Netherland and Slovenia. Shared care by STI/GUM clinics and 
gynaecologists/obstetricians was reported in Greece, Latvia and Norway. Cases are referred to 
dermatology/venereology clinics in the Czech Republic and Greece, or to infectious diseases specialists in Denmark. 
In Spain, cases are treated by neonatologists/paediatricians and gynaecologists/obstetricians. In Sweden, a 
specialist in antenatal care collaborates with a venereologist. 
In 20/23 countries, newborns/infants of a syphilis-positive mothers are monitored in a hospital secondary care 
ward (paediatrics/neonatology). In Hungary and Ireland, the monitoring is done in a hospital outpatient 
clinic/ambulatory war, and in Luxembourg the newborn/infant is monitored by a general practitioner. Denmark and 
Estonia reported that the hospital wards and the outpatient/ambulatory clinics are jointly responsible for 
monitoring the outcome of syphilis exposure or congenital infection in infants. Dermatology/venereology clinics 
(Czech Republic) and paediatric infectious disease units (Greece) support neonatology/paediatric hospital wards in 
the monitoring of infants of syphilis-positive mothers. In the UK, outpatient clinics are responsible for monitoring 
these infants, unless the child’s condition requires inpatient care. 
Testing of children born to syphilis-positive mothers [38] 
Treatment is recommended to newborns diagnosed with congenital syphilis. Asymptomatic neonates born to a 
mother diagnosed with syphilis during pregnancy receive a prophylactic single dose of penicillin. Follow-up tests 
should be arranged at 1, 2, 3, 6 and 12 months to assess response to treatment. Infants with negative serology 
should still have follow-ups at three and six months. 
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Penicillin is the treatment of choice for syphilis in pregnant women in all 24 responding countries. Data about the 
proportion of pregnant women diagnosed with syphilis who are treated during pregnancy were only available from 
Luxembourg and Malta, both reporting a treatment coverage of 100%. Nine other countries (Czech Republic, 
Denmark, Estonia, Finland, Iceland, Slovakia, Slovenia, Spain and Northern Ireland (UK)) provided estimates 
ranging between 80% and 100%. Eleven countries (Belgium, France, Germany, Hungary, Ireland, Italy, Latvia, 
Lithuania, the Netherlands, Norway, Romania and the UK) do not collect data on the proportion of women with 
syphilis who are treated during pregnancy.  
All 24 responding countries treat congenital syphilis with penicillin. 
Populations at risk of mother-to-child transmission of syphilis and 
challenges for effective antenatal screening  
The most commonly recognised risk groups reported by the responding countries as not being reached by 
antenatal syphilis screening programmes were: women reached for screening late in pregnancy, migrants from 
high-prevalence countries outside the EU and PWID (Figure 15).  
The three most common challenges for implementing effective screening policies for syphilis were: the lack of data 
reported and collected at the national level, insufficient capacity to reach groups at risk, and a lack of resources 
(Figure 16).  
Figure 15. Population groups at risk of not being reached by syphilis antenatal screening 
programmes, vulnerable to MTCT of syphilis, EU/EEA, 2013 
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Treatment/prophylaxis of the mother and the child  [39] 
Effective treatment regimens of maternal and fetal infection exist. Penicillin G, administered parenterally, is the 
preferred drug for treating syphilis. Maternal treatment can be inadequate if delivery occurs within 30 days of 
therapy, or if the maternal antibody titer at delivery is four times higher than the pre-treatment titer. 
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Figure 16. Challenges for the implementation of effective antenatal screening policies for syphilis, 
EU/EEA, 2013 
 
3.6 Rubella susceptibility screening: survey results  
Responses to the rubella questionnaire were received from 22/26 countries. Belgium, Portugal, Slovakia and 
Slovenia did not respond. Rubella is a notifiable infection in 24/26 responding EU/EEA countries. Exceptions are 
Denmark (but both rubella infection during pregnancy and congenital rubella are notifiable) and France. In 
Belgium, rubella is notifiable in the Brussels capital region and congenital rubella in the Walloon region. Congenital 
rubella is not notifiable in France.  
Implementation of antenatal screening for rubella susceptibility 
Antenatal rubella susceptibility screening is implemented in 14/26 (59%) countries: Belgium, France, Greece, 
Iceland, Ireland, Italy, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Spain and UK.  
Rubella susceptibility screening has been discontinued due to low incidence of rubella and the high vaccination 
coverage in several countries such as Denmark, Finland, Hungary and Slovenia. Limited resources were mentioned 
by Latvia, Lithuania and Romania as a reason for not recommending susceptibility screening. In the Netherlands, 
although there are no national antenatal screening recommendations, rubella susceptibility testing is offered on the 
recommendation of a doctor or midwife: about 60% screened all pregnant women, 25% offered testing to high-
risk groups including the unvaccinated, and 15% did not offer screening to pregnant women at all. Estonia, 
Germany, Slovenia and Sweden also reported testing of ‘pregnant women in specific groups’.  
The overall aim of antenatal rubella susceptibility testing in Iceland, Ireland, Malta, Norway and Sweden is to 
identify susceptible women who would benefit from post-partum rubella immunisation. The main aim in 
Luxembourg, Poland and Spain is to assist diagnosis in subsequent pregnancies and investigation of the neonate in 
case of maternal exposure to rubella. Both aims are considered equally important in France, Greece and Italy.  
The management of viral rash illness (or exposure to viral rash illness) during pregnancy is addressed in guidance 
for antenatal rubella susceptibility screening in the Czech Republic, Germany, Greece, Luxembourg and Malta. In 
Denmark, France, the Netherlands, Romania, Sweden and the UK, the management is addressed in a separate 
guidance document. No guidance on this topic exists in Estonia, Hungary, Iceland, Ireland, Italy, Norway and 
Poland.  
Funding of antenatal screening for rubella susceptibility 
Rubella susceptibility screening is publicly funded (free of charge) in seven countries. Another 4/11 countries offer 
antenatal syphilis screening through health insurance schemes (Table 14).  
0 1 2 3 4 5 6 7 8 9 10
Congenital syphilis is not a public health priority
Quality of laboratory testing
Lack of resources
Insufficient capacity to reach populations at risk
Lack of/incomplete data reporting/collection at 
national level
FR, GR, IT, LT, MT, RO, SK
GR, IT, LV, MT, SK
DE, SK
IT
EE, FR, DE, GR, IE, IT, LV, LU, SI
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Table 14. Financing of antenatal screening for rubella susceptibility, EU/EEA, 2013 
Publicly funded 
n=7 
Health insurance 
n=4 
IS, IE, IT, MT, NO, ES, UK FR, GR, LU, PL* 
* Poland reported that antenatal screening for uninsured pregnant women was funded through the public health budget. No 
information reported from Belgium, Portugal and Slovakia.  
Data collection, storage and analysis 
Data on antenatal screening for rubella susceptibility is collected, stored and analysed at the national level in 
Ireland, Slovakia and the UK.  
Monitoring or evaluation of the effectiveness of antenatal screening programmes for rubella susceptibility has been 
performed in Ireland, Slovakia and the UK. 
Vaccination policies and coverage  
All EU/EEA countries have childhood vaccination programmes in place for rubella. All programmes administer two 
doses of the measles, mumps and rubella (MMR) vaccine. The year of programme implementation varies, as does 
vaccination coverage: in 2013, national estimates ranged between 86% and 99% for the first dose in 2013  [40].  
Selective rubella vaccinations are recommended for healthcare workers in six countries (Finland, France, Ireland, 
Italy, Norway and Spain) and for migrants from high-prevalence countries inside and outside the EU (Ireland and 
Slovakia). Rubella vaccinations can also be offered to close contacts of confirmed rubella cases, mobile populations, 
to people in pre-conceptual care and to people at risk for occupational reasons. 
Strategies for rubella susceptibility antenatal screening  
The most common (9/14, 64%) strategy of antenatal screening for rubella susceptibility in the EU/EEA is opt-out 
screening, followed by universal screening (4/14, 29%). Luxembourg reported using an opt-in strategy (Figure 17). 
Targeted antenatal rubella susceptibility screening is offered in the case of clinical suspicion or contact with a 
rubella case (Estonia), to those whose immunity is unknown or non-existent (Germany), to the unvaccinated 
(Slovenia) and to those unvaccinated in their the first pregnancy (Sweden). Testing is recommended by doctors or 
midwifes in the Netherlands.  
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Figure 17. Antenatal rubella susceptibility screening strategies, EU/EEA, 2013  
  
Note: Opt-in strategy in Northern Ireland (UK); Estonia, Germany, Netherlands, Slovenia and Sweden: testing targeted to 
pregnant women in specific population groups 
Timing of screening and testing coverage 
Antenatal screening for rubella susceptibility is recommended during the first trimester of pregnancy in 
10/11 countries (France, Greece, Iceland, Ireland, Italy, Luxembourg, Norway, Poland, Spain, and the UK). Malta 
recommends testing as part of pre-conceptual care. Testing during pre-conceptual care is also possible in France, 
Greece, Italy and Spain.  
Rubella susceptibility testing can be done as part of pre-conceptual care in the Czech Republic, Hungary and 
Latvia, three countries that do not run national screening programme. In Germany testing is recommended both as 
part of pre-conceptual care and during the first trimester.  
The percentage of women tested at least once during pregnancy was estimated at over 95% in Ireland, 
Luxembourg, Malta and the UK. Norway estimated the coverage to be 90%, while the Netherlands provided an 
estimate of 60%. 
The proportion of negative tests, reflecting rubella susceptibility in tested pregnant women, was only available from 
Ireland, Malta and the UK: 3.70%, 9.50% and 5.35%, respectively.  
Congenital rubella 
Number of congenital rubella cases reported in the EU/EEA have remained low. Between 2007 and 2012, the 
highest numbers were reported by Italy (26) and Romania (58). In 2013, 49 cases of MTCT of rubella were 
reported by four countries, with 45 by Romania (Table 22)  [41]. 
Table 15. Congenital rubella cases, EU/EEA 2007–2013  
Country 
Congenital rubella cases 
2013 
Congenital rubella cases 
2007–2012 
Belgium 0 1 
Czech Republic 0 2 
Denmark 0 0 
Estonia 0 0 
Finland 0 1 
France - 3 
Germany 1 4 
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Country 
Congenital rubella cases 
2013 
Congenital rubella cases 
2007–2012 
Greece 0 0 
Hungary 0 0 
Iceland 0 0 
Ireland 0 0 
Italy - 26 
Latvia 0 0 
Lithuania 0 0 
Luxembourg 0 0 
Malta - 0 
Netherlands 0 0 
Norway 0 0 
Poland 2 3 
Portugal 0 2 
Romania 45 58 
Slovakia 0 0 
Slovenia 0 0 
Spain 1 6 
Sweden 0 1 
UK 0 2 
Source: adapted from WHO  [41] 
Testing of children born to mothers with rubella infection during early 
pregnancy 
The EU case definition requires that an infant with congenital rubella was laboratory-confirmed with rubella 
infection and shows clinical manifestations suggestive of congenital rubella syndrome, or was born to a woman 
with a laboratory-confirmed rubella infection during pregnancy [42]. Children born to a mother diagnosed with 
rubella during pregnancy are tested for rubella in all 21 responding countries. 
All 21 countries, except Denmark and the UK, use anti-rubella IgM antibody testing to confirm diagnosis of 
congenital rubella. Hungary and Poland also use virus isolation. Denmark uses only NAATs. A combination of virus 
isolation, IgM antibody and nucleic acid testing is used in the Czech Republic, Germany, Ireland, Italy, Latvia, 
Luxembourg, the Netherlands and Spain. IgM antibody testing, together with nucleic acid testing is used in Estonia, 
Finland, France, Greece, Norway and Sweden (Table 23). The UK utilises both NAAT and virus isolation testing.  
In addition, anti-rubella IgG tests are done at six months of age in Romania; in France, this test is conducted at 
12 months. Italy monitors IgG levels in the first year of life, while Spain monitors persistence of IgG antibodies 
from 6 to 12 months of age. 
Table 16. Diagnostic tests used to detect congenital rubella, EU/EEA, 2013  
IgM antibody NAAT IgG antibody Virus isolation 
CZ, EE, FI, FR, DE, GR, HU, IS, IE, 
IT, LV, LT, LU, MT, NL, NO, PL, RO, 
ES, SE 
CZ, DK, EE, FI, FR, DE, GR, IE, IT, 
LV, LU, NL, NO, ES, SE, UK 
 
FR, IT, RO, ES CZ, DE, HU, IE, IT, LV, LU, NL, PL, 
ES, UK 
Note: Northern Ireland uses IgM antibody testing for congenital rubella.  
Rubella: Referral and retention in care  
Pregnant women who are rubella antibody negative are recommended to be vaccinated in the post-partum period 
in all 15 countries that responded (Denmark, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, 
the Netherlands, Norway, Poland, Spain and Sweden). In addition, six countries (France, Germany, Greece, Iceland, 
Italy and Spain) recommend additional laboratory investigations during pregnancy. Denmark, France, Ireland, 
Poland and the UK perform additional laboratory investigations during pregnancy, but only in the in case of rubella 
exposure or if there are clinical signs suggestive of rubella. France recommends an additional antibody test at the 
20th week of gestation. None of the responding EU/EEA countries had data on the proportion of women with a 
negative rubella antibody test that were vaccinated against rubella after delivery. 
Newborns/infants suspected of congenital rubella are monitored in a hospital secondary care ward 
(paediatrics/neonatology) in the Czech Republic, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, 
Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Romania, Spain and Sweden. In nine countries 
(Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy and Sweden) the monitoring is done 
jointly with the hospital outpatient clinic/ambulatory ward. In Germany, Hungary and Italy, newborns can also be 
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monitored in a well-baby clinic in primary care or by a general practitioner. In Norway and the UK, monitoring 
depends on clinical signs and symptoms; in Romania, referral to an infectious disease hospital/ward involvement 
depends on the pathology. 
Populations at risk of mother-to-child-transmission of rubella and 
challenges for effective antenatal screening  
Due to the high vaccination coverage in Europe, vertical transmission of rubella is rare. However, unvaccinated 
cohorts remain still susceptible to infection, particularly migrants from rubella endemic countries and women 
following certain beliefs (Figure 18). 
The three most commonly cited challenges for implementing effective antenatal screening policies for rubella 
susceptibility were: the lack of reporting and deficiencies in data collection at the national level, a lack of resources, 
and insufficient capacity to reach risk groups. Other challenges included difficulties reaching migrant populations. 
Unvaccinated migrant women, for example, may be less likely to seek screening. Also, there are smaller population 
groups who missed MMR vaccination or whose parents refused vaccination. In addition, offering and promoting 
rubella susceptibility tests is often not standard practice among healthcare workers. In some countries, data on 
post-partum vaccination are not collected (Figure 19). 
Figure 18. Population groups reported to be at risk of not being reached by antenatal rubella 
susceptibility screening programmes or vulnerable to MTCT of rubella, EU/EEA, 2013  
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Figure 19. Challenges for the implementation of effective antenatal screening policies for rubella, 
EU/EEA, 2013 survey 
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4 Discussion and conclusions 
Antenatal screening for HIV, HBV, syphilis and rubella susceptibility is widely implemented in the EU/EEA and can 
effectively prevent or reduce mother-to-child transmission. Nonetheless, challenges to programme implementation 
remain, which may explain why mother-to-child transmission is still reported in many European countries. 
4.1 Effectiveness of antenatal screening 
In the vast majority of EU/EEA countries (96%), the provision of antenatal care to pregnant women is based on 
national guidance, screening recommendations or a prevention strategy, sometimes as part of a wider programme 
of antenatal screening for infectious diseases. Antenatal HIV screening programmes are implemented in 
24 countries (all but Hungary and Slovenia). HBV screening programmes are carried out in 23 countries (not in 
Lithuania, the Netherlands and Romania; in Romania screening is recommended but not implemented). Antenatal 
syphilis screening is implemented in all 26 responding countries, whereas rubella susceptibility screening is done in 
14 countries (not in the Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Latvia, Lithuania, the 
Netherlands, Romania, Slovenia and Sweden). Despite the existence of national recommendations, compliance with 
existing guidelines is reported to be less than optimal in several countries [43-48]: in the survey, several free-text 
responses highlighted that implementation is highly variable and often depends on the local general practitioners 
and public health nurses who perform the screening tests.  
Access to antenatal screening for pregnant women is further restricted by insufficient programme funding and 
inadequate preventive measures. Public funding, the strategy adopted by the majority of EU/EEA countries, is 
aimed at easy access to screening, but some subgroups (e.g. undocumented migrants) are not always entitled to 
benefit from public services, which increases their vulnerability to MTCT. Nonetheless, pregnant women from newly 
arrived migrants and asylum seekers may not be aware of their options with regard to antenatal care.  
Opt-out programmes are the most commonly used programmes for the antenatal screening of HIV, HBV, syphilis 
and rubella susceptibility in Member States, followed by universal screening. An opt-out strategy is considered an 
effective way to reach pregnant women – a reasonable compromise between a fully informed consent and 
universal screening [14,23,24,43,49,50]. Some countries targeted women at higher risk of MTCT (i.e. PWID or 
women showing high-risk behaviours). Survey respondents pointed out that these population groups presented a 
significant challenge to the successful prevention of MTCT of HIV, HBV and syphilis.  
The results of this survey clearly show that MTCT – despite all screening strategies and programmes – still occurs, 
albeit at a low level. Reasons for ongoing MTCT in Europe could be that the effectiveness of antenatal screening 
strategies is compromised by factors such as incomplete screening coverage, poor access to antenatal care, or 
inadequate HIV and hepatitis testing among groups at high risk. However, rates of MTCT in EU/EEA countries are 
low across all countries and cases of MTCT are clustered in high-risk subpopulations.  
Evidence from other surveys indicates that the healthcare system fails to recognise and meet the complex needs of 
pregnant women from ethnic minorities: this – in addition to cultural, language and communication barriers – can 
hinder early initiation of antenatal care in this subgroup  [51]. The UK NICE Guideline Developing Group has 
published guidance for antenatal care services for women with complex social factors (defined as women with 
substance misuse, recent arrival as a migrant, asylum seeker or refugee status, difficulty speaking or 
understanding English, age under 20, domestic abuse, poverty and homelessness) [52].  
The high coverage of ART in HIV-positive pregnant women, the EU/EEA-wide recommendation for avoiding 
breastfeeding, and the almost complete antiretroviral prophylaxis coverage in infants born to HIV-positive mothers 
(98–100%, 10/23 countries), may have contributed to the very low rates of HIV MTCT in EU/EEA countries.  
In 2011, the global community defined the elimination of HIV and syphilis MTCT as a public health priority. The 
WHO document ‘Global guidance on criteria and processes for validation: elimination of mother-to-child 
transmission of HIV and syphilis’, outlines processes and criteria for validation of elimination of mother to child 
transmission of HIV and/or syphilis in a country [53]. Overall, the EU/EEA countries that responded to the survey, 
showed that they had either reached, or were very close to reaching, the WHO Global targets for the elimination of 
MTCT of HIV and syphilis.  
According to current survey findings, the proportion of HIV-positive pregnant women newly diagnosed through 
antenatal screening was over 30% in 6/11 countries. If detected late during pregnancy, this considerable 
proportion of women with undiagnosed infection may further contribute to ongoing MTCT transmission. A similar 
figure was reported in a recent publication from the UK: 32% (19/60) of the HIV-positive pregnant women were 
diagnosed during their current pregnancy  [54]. 
A major challenge to antenatal screening identified by the Member States in the survey was the lack of systematic 
collection of specific operational and outcome data on antenatal screening programmes; data on antenatal 
 
 
 
 
TECHNICAL REPORT Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA 
 
 
 
 
37 
 
 
 
screening of HIV are not collected or analysed in half of the surveyed countries, with the percentage even smaller 
for HBV, syphilis and rubella susceptibility screening. Without surveillance data, countries are unable to monitor 
rates of MTCT, properly assess the effectiveness of their antenatal screening strategies, and are limited in their 
ability to respond and adapt to changes in the epidemiology of vertically transmitted infections. Collection, storage 
and analysis of antenatal screening data needs to be strengthened at both national and regional levels. Routine 
monitoring and evaluation of national antenatal screening programmes, including auditing programme 
implementation and measurement of testing coverage seem beneficial.  
Reluctance of medical professionals to offer HIV testing was identified as an obstacle to successful antenatal 
screening by several countries, reflecting that attitudes towards HIV infection still differ from other infectious 
diseases. Reluctance to offer testing can be due to the healthcare professional’s discomfort when approaching the 
subject of HIV, lack of training to increase competence in conducting HIV testing, lack of knowledge on local HIV 
prevalence and transmission routes, unawareness of or lack of local guidance and policies on HIV testing, and 
logistical barriers such as cost, time constraints and consent procedures [55]. 
Finally, a challenge specific to reducing MTCT of HBV is the relationship between screening programmes and 
vaccination policy. Some countries, for example Romania, do not implement antenatal HBV screening, as HBV is 
included in the childhood vaccination programme. However, coverage of HBV vaccination among women of child-
bearing age in several EU/EEA countries has not yet reached a sufficiently high level to be used as a justification 
for discontinuing antenatal screening. If screening is discontinued, it is still necessary to have targeted antenatal 
screening programmes for various vulnerable subpopulations in which vaccination coverage may be substantially 
lower. The six countries (Denmark, Finland, Iceland, Norway, Sweden and the UK) that lack national childhood 
vaccination programmes have a very low population prevalence of HBV (<0.5%). With the exception of Norway, all 
countries report universal screening for HBV, as the vast majority of HBV diagnoses are among migrant populations 
infected in their country of origin. 
4.2 Strengths and limitations of the survey 
Participation in this antenatal screening survey was high, with 26 of 30 (87%) EU/EEA countries responding. Only 
Austria, Bulgaria, Cyprus and Liechtenstein did not participate. Questions were kept short and to the point to 
ensure the survey could be completed in a reasonable amount of time. Disease-specific questionnaires were similar 
in content to assure comparability of the results between diseases. A pilot phase ensured the survey was optimised 
prior to rolling out to all countries. 
However, there are limitations inherent to the survey methodology, which limits the conclusions that can be drawn 
from these data. The response rate for each of the five general or disease-specific questionnaires (HIV, HBV, 
syphilis, rubella) varied. Missing responses could have been due to the unavailability of the appointed responder or 
limited/unavailable/missing data.  
Data accuracy further relied on the interpretation of the questions and the responders’ knowledge or awareness of 
antenatal screening policies. As the questionnaires were filled in by public health officials rather than clinicians, the 
data may reflect policy rather than practice. A recent audit of clinical practice in Ireland showed very low rates of 
compliance with the recommendations for follow-up testing of infants born to HBV-positive mothers in primary care  
[56]. 
Because of the time delay between data collection and publication of this report, some of the information may be 
outdated, e.g. advances in lab testing technologies for HIV and wider access to new testing methods in the 
Member States.  
In terms of the limitations to the numerical data, the low completeness of variables in TESSy for HIV and 
hepatitis B (e.g. country of birth and probable country of infection) made it difficult to identify all MTCT cases born 
in the reporting country, leading to likely underascertainment of mother-to-child transmission in some countries. 
4.3 Final considerations  
Since the rates of MTCT of HIV and congenital syphilis are below the WHO global targets for the elimination in 
most EU/EEA countries, the development of stricter European targets may better fit the low levels of transmission. 
Few countries collect data robust enough for a comprehensive evaluation of antenatal screening programme 
effectiveness and even fewer make the results of such evaluations publically available. As such, the development of 
a set of indicators to guide countries in the monitoring and evaluation of antenatal screening programme 
effectiveness would help.  
In several EU/EEA countries, national surveillance systems do not currently collect all the variables needed to 
identify nationally acquired MTCT infections; in addition, notification of congenital syphilis is not always mandatory. 
The introduction of enhanced surveillance of vertical transmission may improve completeness of reporting and 
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reduce underestimation of MTCT in Europe. Development of MTCT databases may further help identification of the 
risk factors associated with the transmission. 
Ongoing MTCT affects some vulnerable groups that are not reached by or do not have access to testing services 
and prevention interventions available to the general population. Targeted interventions for such populations at 
risk, based on the epidemiological and risk profile of each country settings, should be considered by the Member 
State.  
Reacting to survey findings, ECDC is currently developing evidence-based guidance for strengthening antenatal 
screening among vulnerable groups for the use of national programme coordinators and policy makers. The 
guidance will aim at responding two main questions: which elements of a national antenatal screening programme 
for infections influence effectiveness and which are the specific approaches to be used for reaching the vulnerable 
groups in order to increase the uptake of prenatal care and reduce/prevent MTCT.  
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Annex 1. Responses to the Member State 
survey on antenatal screening 
Country 
Survey questionnaires 
General HIV HBV Syphilis Rubella 
Austria       
Belgium  x x * x  
Bulgaria       
Cyprus       
Czech Republic  x x x x x 
Denmark (pilot) x x x x x 
Estonia  x x x x x 
Finland  x x x x x 
France  x x x x x 
Germany  x x x x x 
Greece  x x x x x 
Hungary  x x x x x 
Iceland  x x x x x 
Ireland  x x x x x 
Italy  x x x x x 
Latvia  x x x x x 
Liechtenstein       
Lithuania  x x x x x 
Luxembourg  x x x x x 
Malta  x x x x x 
Netherlands (pilot) x x x x x 
Norway  x x x x x 
Poland  x x x  x 
Portugal  x     
Romania  x x x x x 
Slovakia  x x  x  
Slovenia  x x  x  
Spain  x x x x x 
Sweden  x x x x x 
United Kingdom  x x x x x 
United Kingdom (Northern Ireland) (pilot) x x x x x 
Note: Denmark, Netherlands and Northern Ireland (UK) participated in the pilot phase of the survey.  
* Belgium provided answers to several questions during the validation phase.  
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Annex 2. Mother-to-child transmission of 
HIV: number of cases and rates per 100 000 
births in persons identified as born in the 
reporting country and cases of congenital 
syphilis  
 HIV MTCT 
Congenital syphilis 
 All ages 0–1 year olds 
Country Cases Rate Cases Rate Cases Rate 
Austria 1 1.3 1 1.3 - - 
Belgium 1 0.8 0 0.0 - - 
Bulgaria 5 7.5 2 3.0 27 40.6 
Cyprus 0 0.0 0 0.0 0 0.0 
Czech Republic 0 0.0 0 0.0 1 0.9 
Denmark 0 0.0 0 0.0 - - 
Estonia 2 14.8 2 14.8 0 0.0 
Finland 1 1.7 1 1.7 - - 
France 13 1.6 9 1.1 - - 
Germany 5 0.7 2 0.3 2 0.3 
Greece 0 0.0 0 0.0 - 0 
Hungary 1 1.1 0 0.0 2 2.2 
Iceland 0 0.0 0 0.0 0 0.0 
Ireland 0 0.0 0 0.0 0 0.0 
Italy 5 1.0 3 0.6 - 0.0 
Latvia 9 43.7 6 29.1 0 0.0 
Liechtenstein - - - - - - 
Lithuania 1 3.3 1 3.3 2 6.7 
Luxembourg 0 0.0 0 0.0 0 0.0 
Malta 0 0.0 0 0.0 0 0.0 
Netherlands 2 1.2 1 0.6 - - 
Norway 1 1.7 1 1.7 0 0.0 
Poland 4 1.1 4 1.1 19 5.1 
Portugal 1 1.2 0 0.0 5 6.0 
Romania 16 9.1 13 7.4 3 1.7 
Slovakia 0 0.0 0 0.0 0 0.0 
Slovenia 0 0.0 0 0.0 0 0.0 
Spain 5 1.2 4 0.9 3 0.7 
Sweden 2 1.8 1 0.9 0 0.0 
United Kingdom 16 2.0 2 0.3 0 0.0 
Total: EU and EEA 91 1.8 53 1.0 64 2.0 
 –: data not available, country does not report to TESSy 
Source: Data retrieved from The European Surveillance System (TESSy), EU/EEA, 2013 
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Annex 3. General questionnaire: antenatal 
screening 
This antenatal screening 2013 survey aims to identify current policies and practices for the antenatal screening for 
HIV, HBV, syphilis and rubella and to recognise points of vulnerability within current systems. 
Please fill in all questions applicable to your country. Leave empty those questions where data are not available. At 
the end of the questionnaire an additional space is provided for comments. 
Use the 'Break' buttons to pause at any time; your answers will be saved. To continue the survey, a link will be 
provided by the system, which can be either saved or sent to your email address. 
1. Country 
2. In the event that your responses will apply only to a region of your country, please specify the region. 
3. Background information 
First name 
Last name 
Email 
Phone 
Organization 
 
4. Does your country have national guidance/recommendation on antenatal care (including pregnancy, antenatal, 
neonatal and post- partum care)? 
□ Yes, please provide a reference or link to the document(s) 
□ No 
 
5. Does your country have national guidance/recommendations/a strategy for antenatal infectious disease 
screening? 
□ Yes 
□ No 
 
6. Which of the following infections are covered by the guidance/ recommendations/strategy? 
□ HIV 
□ HBV 
□ Syphilis 
□ Rubella 
7. Is the screening of infectious diseases integrated into the overall antenatal care? 
 Yes No 
HIV   
HBV   
Syphilis   
Rubella susceptibility   
 
8. Which of the following infections are notifiable in your country? Please indicate where the reporting of the 
transmission mode (mother-to-child transmission, MTCT) is required, if applicable 
 Notifiable MTCT reported 
HIV   
HBV   
Syphilis   
Congenital syphilis    
Rubella susceptibility   
Congenital rubella syndrome    
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9. How is the antenatal screening for infectious diseases implemented in your country? 
 HIV HBV Syphilis Rubella 
Universal screening (no questions asked)     
Screening, opting-in (pregnant woman is offered testing, and if 
she agrees to testing, she must provide explicit consent) 
    
Screening, opting-out (pregnant woman is informed that testing 
will take place as part of the antenatal care, unless she explicitly 
declines) 
    
Selective screening for groups at risk for HIV, please specify     
Selective screening for groups at risk for HBV, please specify     
Selective screening for groups at risk for syphilis, please specify      
Selective screening for groups at risk for rubella, please specify     
Voluntary testing (screening not offered, but available)     
Screening not recommended       
 
10. If the antenatal screening for a given infectious disease is not recommended in your country, please provide 
reasons for this policy. 
 HIV HBV Syphilis Rubella 
Epidemiology does not support the need for screening     
Cost-effectiveness studies do not support screening     
Limited resources     
Other, please specify     
 
11. Is vaccination against the following diseases part of a national childhood vaccination programme in your 
country? Please provide the year of comprehensive implementation, that is, when the targeted/effective coverage 
was reached. 
 Yes No 
HBV   
Rubella    
 
12. What is the vaccination coverage of HBV in the national childhood vaccination programme in your country? 
Please provide data from 2011, if available. 
13. In the event that you have an additional policy for vaccinating selected population groups, please choose 
relevant groups targeted for vaccinations. 
 HBV Rubella 
Epidemiology does not support the need for screening   
People who inject drugs (IDU)     
Sex workers     
Migrants from high prevalence areas outside the EU   
Migrants from high prevalence areas inside the EU     
Healthcare workers    
Other, please specify?   
Additional information, if needed 
 
 
  
 
14. Are data for antenatal screening of infectious diseases collected, stored and analysed in your country 
 HIV HBV Syphilis Rubella 
Nationally     
Regionally      
Data from the private sector are included     
Data are not collected      
Other, please specify     
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15. Has the effectiveness of antenatal screening for infectious diseases been monitored or evaluated in your 
country? 
 Yes No 
HIV   
HBV   
Syphilis   
Rubella susceptibility   
  
16. Please provide any additional information you consider important regarding the antenatal screening for 
infectious diseases in your country. You can also add here the links you could not fit in the previous boxes. 
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Annex 4. Questionnaire: antenatal HIV 
screening  
This antenatal screening 2013 survey aims to identify current policies and practices for the antenatal screening for 
HIV and to recognise points of vulnerability within current systems. 
Please fill in all questions applicable to your country. Leave empty those questions where data are not available. At 
the end of the questionnaire an additional space is provided for comments. 
Use the 'Break' buttons to pause at any time; your answers will be automatically saved. To continue the survey, a 
link will be provided by the system, which can be either saved or sent to your email address. 
1. Country 
2. In the event that your responses will apply only to a region of your country, please specify the region 
3. Background information 
First name 
Last name 
Email 
Phone 
Organization 
Section 1: Antenatal assessment and screening for HIV 
4. Is antenatal screening for HIV implemented in your country? 
□ Yes 
□ No 
5. How is the antenatal screening for HIV financed? 
□ Publicly funded (the test is offered free of charge) 
□ Funded by health insurance (the test is funded through pre-existing health insurance) 
□ At the personal cost of the person screened 
□ Other, please specify 
6. In which healthcare settings (or by which medical professionals) the antenatal screening is routinely offered? 
Please rank in the order of importance (1=most important , 6=least important) from the following options. You can 
add your own, if necessary, and leave irrelevant options empty 
 1 2 3 4 5 6 
General practitioner       
Midwifes       
Family planning clinics       
Obstetrician/gynaecologist        
Any other specialist physician        
Other, please specify        
 
7. During antenatal care visits, is the following information regarding the risks of HIV transmission recommended to 
be communicated to the pregnant woman? 
□ Risk of in utero transmission of HIV 
□ Risk of transmission of HIV during birth 
□ Risk of transmission of HIV during breastfeeding 
8. What is the test used for antenatal screening of HIV? 
□ Antibody testing 
□ Antibody/antigen serology (HIV Combo) 
□ Nucleic acid test (NAT) 
□ Rapid point of care antibody test (blood or saliva) 
□ Other, please specify 
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9. When during pregnancy is the screening test for HIV recommended? 
□ During the first trimester 
□ During the second trimester 
□ During the third trimester 
□ During delivery, if not tested earlier 
□ Other, please specify 
10. Please provide an estimate of the proportion (%) of pregnant women tested early in pregnancy (during the 
first trimester) 
11. In your national/regional data collection on HIV infection and pregnancy, can you distinguish between newly 
diagnosed HIV infection and HIV infections diagnosed before the current pregnancy? 
□ Yes 
□ No 
Please, provide explanation, if needed 
12. How many pregnant women are tested for HIV? Please provide data from 2011, if available, or choose the 
most recent year 
Number of women tested and explanation, if needed 
13. To the best of your knowledge, what proportion of pregnant women are tested for HIV at least once during 
pregnancy? Please provide data from 2011, if available, or choose the most recent year 
% and explanation, if needed 
14. How many tests were performed in antenatal screening for HIV? This number will be used when information on 
the number of pregnant women tested is not available. Please provide data from 2011, if available, or choose the 
most recent year 
Number of HIV tests and explanation, if needed 
15. How many HIV-positive pregnant women were reported in your country? Please provide data from 2011, if 
available or choose the most recent year 
Number of HIV-positive pregnant women and explanation, if needed 
16. How many of the pregnant women tested were newly diagnosed HIV cases? Please provide data from 2011, if 
available or choose the most recent year 
Number of newly diagnosed HIV-positive pregnant women 
17. Is the child born to a HIV-positive mother tested for HIV? 
□ Yes, at birth 
□ Yes, when the infant is aged (specify in months) 
□ Yes, more than once. Please specify the age at the time of the last test (in months) 
□ Other, please specify 
□ No 
18. To the best of your knowledge, what proportion of children born to HIV-positive mothers are tested for HIV at 
least once after birth? Please provide data from 2011, if available, or choose the most recent year 
19. What is the test method used for the diagnosis of HIV infection in a child born to a HIV-positive mother? 
□ Antibody/antigen serology (HIV Combo) 
□ Nucleic acid test (NAT) 
□ Other, please specify 
□ There is no testing for HIV for children born to HIV-positive mothers in my country 
Section 2: Intervention and management of HIV during pregnancy, antenatal and neonatal period. 
20. To whom or where is the HIV-positive pregnant woman referred to for HIV infection care? 
□ Sexually transmitted infections (STI)/genito-urinary medicine (GUM) clinic 
□ Gynaecologist/obstetrician 
□ HIV treatment centre/clinic 
□ Other, please specify 
21. Is the antiretroviral treatment of HIV-positive pregnant women (who have not been in treatment before the 
pregnancy) for the prevention of mother-to-child transmission implemented as 
□ Monotherapy 
□ Combination treatment of two drugs 
□ Combination treatment of three drugs 
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□ Other, please specify 
22. What is the proportion of all pregnant women with HIV infection who receive antiretroviral treatment or 
prophylaxis during pregnancy? 
□ Reported proportion 
□ Estimated proportion 
□ Data is not available 
23. Is Caesarean section recommended in your country for the prevention of mother-to-child transmission of HIV 
during birth? 
□ Yes 
□ No 
□ Other, please specify 
24. Is avoiding breastfeeding recommended in your country for the prevention of mother-to-child transmission of 
HIV? 
□ Yes 
□ No 
25. Is the antiretroviral prophylaxis for children born to HIV-positive mothers implemented as 
□ Monotherapy 
□ Combination treatment of two drugs 
□ Combination treatment of three drugs 
□ Other, please specify 
26. What is the proportion of children born to HIV-positive mothers who receive antiretroviral prophylaxis? 
□ Reported proportion 
□ Estimated proportion 
□ Data is not available 
27. Where is the infection status of the newborn/infant born to a HIV-positive mother monitored? 
□ Neonatologist/paediatrician 
□ HIV treatment centre/clinic 
□ Combination of the two 
□ Other, please specify 
28. What is the proportion of newborn children with confirmed HIV infection who have become enrolled in HIV 
care? 
□ Reported proportion 
□ Estimated proportion 
□ Data is not available 
□ Additional explanation, if needed 
29. How many vertical transmissions of HIV were there in children born in your country during the last five years? 
If possible, please exclude any children who were born abroad. Otherwise provide the total number and indicate 
below that your data may include children born abroad. 
□ 2011 
□ 2010 
□ 2009 
□ 2008 
□ 2007 
□ We cannot distinguish vertical transmissions of HIV based on the country the child was born in 
30. When cases of mother-to-child transmission are reported and the information is available, please list factors 
which are frequently associated with vertical transmission 
Section 3: Vulnerable populations and determinants for mother-to-child transmission. 
31. From the list below, which are the population groups at risk of not being reached by the antenatal screening 
for HIV, and can be considered vulnerable to mother-to-child transmission of HIV in your country? For those you 
consider vulnerable population groups, please fill in your own estimate for the screening coverage percentage. 
□ Women reached for screening late in pregnancy 
□ Economically challenged/poor 
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□ People who inject drugs (IDU) 
□ Sex workers 
□ Female partners of bisexual men 
□ Migrants from high prevalence areas outside the EU 
□ Intra-EU citizen migrants 
□ Mobile populations (populations without permanent residence) 
□ Ethnic minorities not part of the above groups, please specify 
□ Ideological minorities, e.g. based on faith and conviction 
□ Women with multiple sexual partners 
□ Women whose partner belongs to above groups 
□ Healthcare workers 
□ Other, please specify? 
Section 4: Self-assessment of challenges for effective antenatal screening and mother-to-child transmission 
elimination. 
32. What are the challenges (if any) for the implementation of effective antenatal screening policies for HIV in your 
country? 
□ Lack of resources 
□ Lack of data reporting/collection at national level 
□ Unclear delineation of responsibilities 
□ HIV mother to child transmission is not a public health priority 
□ Inadequate political support for HIV screening in pregnancy 
□ Reluctance of medical professionals to offer the HIV testing 
□ Insufficient capacity to reach populations at risk 
□ Other, please specify 
33. Please provide any additional information you consider important regarding the antenatal screening of HIV in 
your country (e.g. what works well or provide an example of good practice). Links to antenatal screening audit 
reports or effectiveness studies are welcomed. 
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Annex 5. Questionnaire: antenatal HBV 
screening  
This antenatal screening 2013 survey aims to identify current policies and practices for the antenatal HBV 
screening and to recognise points of vulnerability within current systems. 
Please fill in all questions applicable to your country. Leave empty those questions where data are not available. At 
the end of the questionnaire an additional space is provided for comments. 
Use the 'Break' buttons to pause at any time; your answers will be automatically saved. To continue the survey, a 
link will be provided by the system, which can be either saved or sent to your email address 
1. Country 
2. In the event that your responses will apply only to a region of your country, please specify the region 
3. Background information 
First name 
Last name 
Email 
Phone 
Organization 
Section 1: Antenatal assessment and screening for HBV 
4. Is antenatal HBV screening implemented in your country? 
□ Yes 
□ No 
5. How is the antenatal HBV screening financed? 
□ Publicly funded (the test is offered free of charge) 
□ Funded by health insurance (the test is funded through pre-existing health insurance) 
□ At the personal cost of the person screened 
□ Other, please specify 
6. In which healthcare settings (or by which medical professionals) the antenatal screening is routinely offered? 
Please rank in the order of importance 
(1= most important , 6= least important) from the following options. You can add your own, if necessary, and 
leave irrelevant options empty 
 1 2 3 4 5 6 
General practitioner       
Midwifes       
Family planning clinics       
Obstetrician/gynaecologist        
Any other specialist physician        
Other, please specify        
 
7. During antenatal care visits, is the risk of in utero transmission of HBV recommended to be communicated to the 
pregnant woman? 
□ Yes 
□ No 
8. What is the test used for antenatal screening of HBV? 
□ HBV surface antigen test (HBsAg) 
□ HBV 'e' antigen test (HBeAg) 
□ Nucleic acid test (NAT) 
□ Other, please specify 
9. When during pregnancy is the screening test for HBV recommended? 
□ During the first trimester 
□ During the second trimester 
□ During the third trimester 
□ During delivery, if not tested earlier 
□ Other, please specify 
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10. In your national/regional data collection on HBV infection and pregnancy, can you distinguish between newly 
diagnosed HBV infection and HBV infections diagnosed before the current pregnancy? 
□ Yes 
□ No 
Please, provide explanation, if needed 
11. How many pregnant women are tested for HBV? Please provide data from 2011, if available, or choose the 
most recent year 
Number of women tested and explanation if needed 
12. To the best of your knowledge, what proportion of pregnant women are tested for HBV at least once during 
pregnancy? Please provide data from 2011 if available or choose the most recent year. 
 
13. How many tests were performed in antenatal HBV screening? This number will be used when information on 
the number of pregnant women tested is not available. Please provide data from 2011, if available, or choose the 
most recent year 
Number of HBV tests and explanation, if needed 
14. How many HBV positive pregnant women were reported in your country? Please provide data from 2011, if 
available, or choose the most recent year 
Number of HBV positive pregnant women and explanation, if needed 
15. How many of the pregnant women tested were newly diagnosed HBV cases? Please, provide data from 2011, if 
available or choose the most recent year 
Number of newly diagnosed HBV positive women 
16. Is the child born to a HBV positive mother tested for HBV? 
□ Yes, once. At when the infant is aged (specify in months) 
□ Yes, twice. The last test is made when the infant aged (specify in months) 
□ Yes, more than twice. Please specify the number of tests and the infant's age at the time of the last test (specify 
in months) 
□ Other, please specify 
□ No 
17. To the best of your knowledge, what proportion of children born to mothers with HBV (chronic carriers or acute 
infections) are tested for HBV at least once after birth? Please provide data from 2011, if available or choose the 
most recent year. 
 
18. What is the test method used for the diagnosis of HBV infection in a child born to a HBV positive mother? 
□ HBV surface antigen test (HBsAg) 
□ Nucleic acid test (NAT) 
□ Other, please specify 
□ There is no testing for hepatitis for children born to HBV positive mothers in my country 
19. Is any testing performed to confirm the seroconversion as a result of vaccination of the child born to a HBV 
positive mother? 
□ Yes 
□ No 
Please, provide explanation, if needed 
Section 2: Intervention and management of HBV during pregnancy, antenatal and neonatal period. 
20. To whom or where is the HBV positive pregnant woman referred to for the HBV infection care? 
□ Sexually transmitted infections (STI)/ genito-urinary medicine (GUM) clinic 
□ Gynaecologist/obstetrician 
□ Hepatologist/gastroenterologist 
□ General physician 
□ Other, please specify 
21. What is the proportion of pregnant women with positive HBV test result referred on to specialist care? 
□ Reported proportion 
□ Estimated proportion 
□ Data is not collected 
22. Where is the infection status of the newborn/infant born to a HBV positive mother monitored? 
□ Obstetrician 
□ Paediatrician 
□ Hepatology specialist 
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□ Other hospital service 
□ Primary care 
□ Other, please specify 
□ No monitoring 
23. Is the prevention of mother-to-child transmission for children born to HBV positive mothers implemented as 
□ Vaccination, the first dose administered within 24 hours of birth 
□ Administration of HBV immunoglobulin 
□ Administration of antiviral drug prophylaxis, please specify 
Additional explanation, if needed 
24. How many vertical transmissions were there of HBV in children born in your country during the last five years? 
If possible, please exclude any children who were born abroad. Otherwise provide the total number and indicate 
below whether your data includes children born abroad 
□ 2011 
□ 2010 
□ 2009 
□ 2008 
□ 2007 
□ We cannot distinguish vertical transmissions of HBV based on the country the child was born in or in the event of 
late manifestation 
25. When cases of mother-to-child transmission are reported and the information is available, please list factors 
which are frequently associated with vertical transmission 
Section 3: Vulnerable populations and determinants for mother-to-child transmission. 
26. From the list below, which are the population groups at risk of not being reached by the antenatal HBV 
screening, and can be considered vulnerable for the mother-to-child transmission of HBV in your country? For 
those you consider vulnerable population groups, please fill in your own estimate for the screening coverage 
percentage. 
□ Women reached for screening late in pregnancy 
□ Economically challenged/poor 
□ People who inject drugs (IDU) 
□ Sex workers 
□ Female partners of bisexual men 
□ Migrants from high prevalence areas outside the EU 
□ Intra-EU citizen migrants 
□ Mobile populations (populations without permanent residence) 
□ Ethnic minorities not part of the above groups, please specify 
□ Ideological minorities, e.g. based on faith and conviction 
□ Women with multiple sexual partners 
□ Women whose partner belongs to above groups 
□ Healthcare workers 
□ Other, please specify 
Section 4: Self-assessment of challenges for effective antenatal screening and mother-to- child transmission 
elimination. 
27. What are the challenges (if any) of implementing policies on antenatal HBV screening? 
□ Lack of resources 
□ Lack of data reporting/collection at national level 
□ Unclear delineation of responsibilities 
□ HBV mother to child transmission is not a public health priority 
□ Inadequate political support for HBV screening in pregnancy 
□ Reluctance of medical professionals to offer HBV testing 
□ Insufficient capacity to reach populations at risk 
□ Other, please specify 
28. Please provide any additional information you consider important regarding antenatal screening of HBV in your 
country (e.g. what works well or provide an example of good practice). Links to antenatal screening audit reports 
or effectiveness studies are welcomed. 
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Annex 6. Questionnaire: antenatal syphilis 
screening  
This antenatal screening 2013 survey aims to identify current policies and practices for the antenatal screening for 
syphilis and to recognise points of vulnerability within current systems. 
Please fill in all questions applicable to your country. Leave empty those questions where data are not available. At 
the end of the questionnaire an additional space is provided for comments. 
Use the 'Break' buttons to pause at any time; your answers will be automatically saved. To continue the survey, a 
link will be provided by the system, which can be either saved or sent to your email address. 
1. Country 
2. In the event that your responses will apply only to a region of your country, please specify the region 
3. Background information 
First name 
Last name 
Email 
Phone 
Organization  
Section 1: Antenatal assessment and screening for syphilis 
4. Is antenatal screening for syphilis implemented in your country? 
□ Yes 
□ No 
5. How is the antenatal screening for syphilis financed? 
□ Publicly funded (the test is offered free of charge) 
□ Funded by health insurance (the test is funded through pre-existing health insurance) 
□ At the personal cost of the person screened 
□ Other, please specify 
6. In which healthcare settings (or by which medical professionals) the antenatal screening is routinely offered? 
Please rank in the order of importance (1= most important , 6= least important) from the following options. You 
can add your own, if necessary, and leave irrelevant options empty 
 1 2 3 4 5 6 
General practitioner       
Midwifes       
Family planning clinics       
Obstetrician/gynaecologist        
Specialist physician (sexually transmitted illness or infectious disease)        
Other, please specify        
 
7. During antenatal care visits, is the risk of in utero transmission of syphilis recommended to be communicated to 
the pregnant woman? 
□ Yes 
□ No 
8. Is there a policy for partner tracing and treatment for the sexual contact(s) of a pregnant woman found positive 
for syphilis? 
□ Yes 
□ No 
□ Please, provide explanation, if needed 
9. What is the test used for antenatal screening of syphilis? 
□ Non-specific treponemal tests (e.g. RPR (rapid plasma reagin) or VDRL (venereal disease research laboratory)) 
□ Specific treponemal tests (e.g. TPHA (Treponema Pallidum Hemaglutination Assay, FTA-ABS (fluorescent 
treponemal antibody absorption assay) 
□ Nucleic acid test (NAT) 
□ Rapid point of care test 
□ Other, please specify 
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10. When during pregnancy is the screening test for syphilis recommended? 
□ During the first trimester 
□ During the second trimester 
□ During the third trimester 
□ During delivery, if not tested earlier 
□ Other, please specify 
Additional explanation, if needed 
12. How many pregnant women are tested for syphilis? Please provide data from 2011, if available, or choose the 
most recent year 
Number of women tested and explanation if, needed 
13. To the best of your knowledge, what proportion of pregnant women are tested for syphilis at least once during 
pregnancy? Please provide data from 2011, if available, or choose the most recent year 
% and explanation, if needed 
14. How many tests were performed for antenatal screening for syphilis? This number will be used when 
information on the number of pregnant women tested is not available. Please provide data from 2011, if available, 
or choose the most recent year 
Number of syphilis tests and explanation, if needed 
15. How many syphilis positive pregnant women were reported in your country? Please provide data from 2011, if 
available, or choose the most recent year 
Number of syphilis positive pregnant women and explanation, if needed 
16. Is the child born to a mother diagnosed with syphilis during pregnancy tested for syphilis? 
□ Yes, once. When the infant is aged (specify in months) 
□ Yes, twice. The last test is made when the infant is aged (specify in months) 
□ Yes, more than twice. Please specify the number of tests and the infant's age at the time of the last test (in 
months) 
□ Other, please specify 
□ No, if the mother has been treated for syphilis 
□ No 
17. What is the test method used for diagnosis of congenital syphilis? 
□ Non-specific treponemal tests (e.g. RPR (rapid plasma reagin) or VDRL (venereal disease research laboratory)) 
□ Specific treponemal tests (e.g. TPHA (Treponema Pallidum Hemaglutination Assay, FTA-ABS (fluorescent 
treponemal antibody absorption assay)) 
□ Nucleic acid test (NAT) 
□ Rapid point of care test 
□ Other, please specify 
□ There is no testing for syphilis for children 
Section 2: Intervention and management of syphilis during pregnancy, antenatal and neonatal period. 
18. To whom or where is the syphilis positive pregnant woman referred to for the syphilis infection care? 
□ Sexually transmitted infections (STI)/ genito-urinary medicine (GUM) clinic 
□ Gynaecologist/obstetrician 
□ Combination of the two 
□ Other, please specify 
19. What is the drug of choice for the treatment of syphilis in pregnant women? 
□ Penicillin 
□ Other, please specify 
20. What is the proportion of pregnant women diagnosed with syphilis who are treated during pregnancy? 
□ Reported proportion 
□ Estimated proportion 
□ Data is not collected 
21. What is the drug of choice for the treatment of congenital syphilis? 
□ Penicillin 
□ Other, please specify 
22. Where is the newborn/infant born to a syphilis positive mother monitored when congenital syphilis is 
suspected? 
□ Hospital outpatient clinic/ambulatory care ward 
□ Well-baby clinic in primary care or general practitioner (GP) 
□ Hospital secondary care ward (paediatrics/neonatology) 
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□ No monitoring recommended 
□ Other, please specify 
23. How many congenital syphilis cases were there in children born in your country during the last five years? If 
possible, please exclude any children who were born abroad. Otherwise, provide the total number and indicate 
below that your data may include children born abroad. 
□ 2011 
□ 2010 
□ 2009 
□ 2008 
□ 2007g 
□ We cannot distinguish congenital syphilis cases based on the country the child was born in 
24. When cases of congenital syphilis are reported and the information is available, please list factors which are 
frequently associated with vertical transmission 
Section 3: Vulnerable populations and determinants for mother to child transmission. 
25. From the list below, which are the population groups at risk of not being reached by the antenatal screening 
for syphilis, and can be considered vulnerable to mother to child transmission of syphilis in your country? For those 
you consider vulnerable population groups, please fill in your own estimate 
for the screening coverage percentage. 
□ Women reached for screening late in pregnancy 
□ Economically challenged/poor 
□ People who inject drugs (IDU) 
□ Sex workers 
□ Female partners of bisexual men 
□ Migrants from high prevalence areas outside the EU 
□ Intra-EU citizen migrants 
□ Women with multiple sexual partners 
□ Women whose partner belongs to above groups 
□ Other, please specify? 
Section 4: Self-assessment of challenges for effective antenatal screening and mother-to-child transmission 
elimination. 
26. What are the challenges (if any) of implementing policies on antenatal screening for syphilis? 
□ Lack of resources 
□ Lack of data reporting/collection at national level 
□ Unclear delineation of responsibilities 
□ Congenital syphilis is not a public health priority 
□ Inadequate political support for syphilis screening in pregnancy 
□ Reluctance of medical professionals to offer the syphilis testing 
□ Insufficient capacity to reach populations at risk 
□ Other, please specify 
27. Please provide any additional information you consider important regarding antenatal screening of syphilis in 
your country (e.g. what works well or provide an example of good practice). Links to antenatal screening audit 
reports or effectiveness studies are welcomed. 
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Annex 7. Questionnaire: rubella susceptibility 
screening in pregnancy 
This antenatal screening 2013 survey aims to identify current policies and practices for the antenatal screening for 
rubella susceptibility and to recognise points of vulnerability within current systems. 
Please fill in all questions applicable to your country. Leave empty those questions where data are not available. At 
the end of the questionnaire an additional space is provided for comments. 
Use the 'Break' buttons to pause at any time; your answers will be automatically saved. To continue the survey, a 
link will be provided by the system, which can be either saved or sent to your email address. 
1. Country 
2. In the event that your responses will apply only to a region of your country, please specify the region 
3. Background information 
First name 
Last name 
Email 
Phone 
Organization 
Section 1: Antenatal assessment, screening for rubella susceptibility, intervention and management of rubella 
during pregnancy, antenatal and neonatal period 
4. Is antenatal screening for rubella susceptibility implemented in your country? 
□ Yes 
□ Yes, in some regions of the country, please specify  
□ No 
5. What is the overall aim of antenatal care for rubella in your country? 
□ To identify susceptible women who would benefit from rubella immunisation post-partum 
□ To assist diagnosis in later pregnancy and investigation of the neonate in case of maternal exposure to rubella 
□ Other, please specify 
6. Is the management of viral rash illness or exposure to viral rash illness in pregnancy addressed in the guidance 
for antenatal rubella susceptibility screening? 
□ Yes, in the same guidance 
□ No, in a separate guidance, please provide a reference or link to the document 
□ No guidance related to the management of viral rash illness or exposure to viral rash illness in pregnancy exists. 
7. How is the antenatal rubella susceptibility screening financed? 
□ Publicly funded (the test is offered free of charge) 
□ Funded by health insurance (the test is offered based on a pre-existing health insurance) 
□ At the personal cost of the person screened 
□ Other, please specify 
8. In which healthcare settings (or by which medical professionals) the antenatal screening is routinely offered? 
Please rank in the order of importance (1=most important, 6=least important) from the following options. You can 
add your own, if necessary, and leave irrelevant options empty 
 1 2 3 4 5 6 
General practitioner       
Midwifes       
Family planning clinics       
Obstetrician/gynaecologist        
Specialist physician        
Other, please specify        
 
9. When is the rubella susceptibility screening test recommended? 
□ As part of preconceptual care 
□ During the first trimester 
□ During the second trimester 
□ During the third trimester 
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10. How many pregnant women are tested for rubella antibodies? Please provide data from 2011, if available, or 
choose the most recent year 
Number of women tested and explanation, if needed 
11. To the best of your knowledge, what proportion of pregnant women undergo antenatal screening for rubella at 
least once during pregnancy? Please provide data from 2011, if available, or choose the most recent year % and 
explanation, if needed 
12. How many tests were performed for antenatal screening for rubella antibodies? This number will be used when 
information on the number of pregnant women tested is not available. Please provide data from 2011, if available, 
or choose the most recent year 
Number of tests and explanation, if needed 
13. What proportion of the tested women were negative for rubella antibodies? Please provide data from 2011, if 
available, or choose the most recent year 
□ 2011 
□ 2010 
□ 2009 
14. What is the follow-up of the rubella antibody negative pregnant women? Please, leave empty in case there is 
no antenatal rubella susceptibility screening in your country. 
□ No particular follow-up 
□ Need for additional laboratory investigation during pregnancy 
□ Need for additional laboratory investigation during pregnancy only in case of exposure to a case or clinical signs 
suggestive of rubella 
□ Recommendation for vaccination in the post-partum period 
□ Other, please specify 
15. What proportion of the pregnant women with a negative test result for rubella antibodies are not vaccinated 
against rubella after delivery? 
□ Reported proportion 
□ Estimated proportion 
16. During antenatal care visits, are the risk factors for rubella infection during pregnancy (including travel to 
endemic countries) recommended to be communicated to the pregnant woman? 
□ Yes 
□ No 
17. Is the child born to a mother diagnosed with rubella during pregnancy tested for rubella? 
□ Yes 
□ No 
18. What is the test method used for confirmation of a diagnosis of congenital rubella? 
□ Virus isolation 
□ Antibody testing (IgM) 
□ Nucleic acid test (NAT) 
□ Other, please specify 
19. Is termination of pregnancy recommended in cases of confirmed rubella infection during pregnancy? 
□ Yes, during the first trimester 
□ Yes, during the second trimester 
□ No 
Additional explanation, if needed 
20. Where is the newborn/infant monitored when congenital rubella is suspected? 
□ Hospital outpatient clinic/ambulatory care ward 
□ Well baby clinic in primary care or general practitioner (GP) 
□ Hospital secondary care ward (paediatrics/neonatology) 
□ Other, please specify 
21. How many congenital rubella syndrome cases were there in children born in your country during the last five 
years? If possible, please exclude any children who were born abroad. Otherwise, provide the total number and 
indicate below that your data may include children born abroad. 
□ 2011 
□ 2010 
□ 2009 
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□ 2008 
□ 2007 
□ We cannot distinguish congenital rubella cases based on the country the child was born in 
Section 2: Vulnerable populations and determinants for mother-to-child transmission. 
22. From the list below, which are the population groups at risk of not being reached by the antenatal rubella 
susceptibility screening, and can be considered vulnerable to mother-to-child transmission of rubella in your 
country? To those you consider vulnerable population groups, please fill in your own estimate for the screening 
coverage percentage. 
□ Women in first pregnancy 
□ Women with no documented vaccination or disease history 
□ Migrants from rubella endemic countries 
□ Ideological minorities, e.g. based on faith and conviction 
□ Other, please specify 
Section 3: Self-assessment of challenges for effective antenatal screening and mother-to -child transmission 
elimination. 
23. What are the challenges (if any) of implementing policies on rubella susceptibility screening? 
□ Lack of resources 
□ Lack of data reporting/collection at national level 
□ Unclear delineation of responsibilities 
□ Congenital rubella is not a public health priority 
□ Inadequate political support for rubella susceptibility screening in pregnancy 
□ Reluctance of medical professionals to offer rubella testing 
□ Insufficient capacity to reach populations at risk 
□ Other, please specify 
24. Please provide any additional information you consider important regarding rubella susceptibility screening in 
your country (e.g. what works well or provide an example of good practice). Links to antenatal screening audit 
reports and effectiveness studies are welcome 
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